H. Lundbeck A/S et al v. Lupin Limited, et al
Takeda Pharmaceuticals International AG, H. Lundbeck A/S, Takeda Pharmaceuticals U.S.A., Inc. and Takeda Pharmaceuticals America, Inc. |
Apotex Inc., Apotex Research Private Limited, Apotex Corp., Lek Pharmaceuticals d.d., Alembic Global Holding S/A, Macleods Pharma USA, Inc., Cipla Limited, Cipla USA Inc., Zydus Pharmaceuticals (USA) Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Amneal Pharmaceuticals of New York LLC, Macleods Pharmaceuticals Ltd., MSN Pharmachem Private Limited, MSN Laboratories Private Limited, Hetero USA Inc., Hetero Labs Limited, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc., Alkem Laboratories Ltd., MSN Pharmaceuticals Inc., Cadila Healthcare Ltd., Amneal Pharmaceuticals Pvt. Ltd., Prinston Pharmaceutical Inc., Amneal Pharmaceuticals Company GmbH, Sigmapharm Laboratories LLC, Apicore US LLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd, Lupin Pharmaceuticals Inc., Hetero Labs Limited Unit-V, Sandoz AG, Sandoz Inc. and Lupin Limited |
Takeda Pharmaceutical Company Ltd. |
Unichem Laboratories, Limited |
1:2018cv00088 |
January 12, 2018 |
US District Court for the District of Delaware |
Wilmington Office |
New Castle |
Leonard P Stark |
Patent - Abbreviated New Drug Application(ANDA) |
35 U.S.C. § 271 Patent Infringement |
Defendant |
Docket Report
This docket was last retrieved on December 16, 2021. A more recent docket listing may be available from PACER.
Document Text |
---|
Filing 1102 TRANSCRIPT REQUEST -- Transcript Purchase Order -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. before Judge The Honorable Leonard P. Stark. (Dellinger, Megan) |
Filing 1101 NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re #1098 Notice of Cross Appeal filed by Lek Pharmaceuticals D.D., Sandoz Inc. USCA Case Number 2022-1246. (ntl) |
Filing 1100 TRANSCRIPT REQUEST by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) |
Filing 1099 TRANSCRIPT REQUEST by Lek Pharmaceuticals D.D., Sandoz Inc. before Judge Leonard P. Stark, (Gattuso, Dominick) |
Filing 1098 NOTICE OF CROSS APPEAL to the Federal Circuit of #1090 Judgment . Cross Appeal filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Gattuso, Dominick) |
Notification regarding #1098 Notice of Cross Appeal sent to Reporter Gaffigan (myr) |
APPEAL - Credit Card Payment of $505.00 received re #1098 Notice of Cross Appeal filed by Lek Pharmaceuticals D.D., Sandoz Inc.. ( Filing fee $505, receipt number ADEDC-3758535.) (Gattuso, Dominick) |
Notification regarding #1098 Notice of Cross Appeal sent to Reporter Gunning (myr) |
Notice of Cross Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re #1098 Notice of Cross Appeal. (myr) |
Filing 1097 CORRECTED CONSENT JUDGMENT regarding Torrent Pharmaceuticals Limited and Torrent Pharma Inc. Signed by Judge Leonard P. Stark on 12/2/21. Associated Cases: 1:18-cv-00088-LPS, 1:18-cv-00149-LPS, 1:18-cv-00672-LPS (ntl) |
Filing 1096 NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re #1093 Notice of Appeal (Federal Circuit) filed by Lupin Pharmaceuticals Inc., Lupin Limited. USCA Case Number 2022-1208. (ntl) |
Filing 1095 PROPOSED CONSENT JUDGMENT (Corrected) by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Connolly, Arthur) |
Filing 1094 NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re #1092 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. USCA Case Number 2022-1194. (ntl) |
Filing 1093 NOTICE OF APPEAL to the Federal Circuit of #1090 Judgment, #1076 Order, #1075 Opinion . Appeal filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) |
Notification regarding #1093 Notice of Appeal (Federal Circuit) sent to Reporter Gaffigan. (nmg) |
APPEAL - Credit Card Payment of $505.00 received re #1093 Notice of Appeal (Federal Circuit) filed by Lupin Pharmaceuticals Inc., Lupin Limited. ( Filing fee $505, receipt number ADEDC-3751130.) (Lennon, James) |
Notification regarding #1093 Notice of Appeal (Federal Circuit) sent to Reporter Gunning. (nmg) |
Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re #1093 Notice of Appeal (Federal Circuit). (nmg) |
Filing 1092 NOTICE OF APPEAL to the Federal Circuit of #912 Order, 801 Oral Order,,,,,,,,,,,,,, #357 Memorandum Opinion, #358 Order, #1090 Judgment, #682 Memorandum Opinion, #683 Order . Appeal filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
APPEAL - Credit Card Payment of $505.00 received re #1092 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc.. ( Filing fee $505, receipt number ADEDC-3750309.) (Dellinger, Megan) |
Notification regarding #1092 Notice of Appeal (Federal Circuit), sent to Reporter Gaffigan (mal) |
Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re #1092 Notice of Appeal (Federal Circuit),. (mal) |
Notification regarding #1092 Notice of Appeal (Federal Circuit), sent to Reporter Gunning (mal) |
Filing 1091 Report to the Commissioner of Patents and Trademarks. (ntl) |
Filing 1090 FINAL JUDGMENT (See document for further details) (CASE CLOSED). Signed by Judge Leonard P. Stark on 10/28/21. (ntl) |
Filing 1089 ORAL ORDER: Having reviewed the parties' Proposed Final Judgment (D.I. 1085), as well as Plaintiffs' and Lupin's letters relating to a dispute in connection with that proposal (see D.I. 1083, 1084, 1086, 1087), IT IS HEREBY ORDERED that Plaintiffs' request that Lupin be enjoined from launching its products until after the expiration of the '626 Patent is DENIED WITHOUT PREJUDICE to renew after the completion of any appellate process. On the record as it presently exists, the Court agrees with Lupin that Plaintiffs have failed to show they will be irreparably injured by any action Lupin may take (with respect to its proposed drug product) between now and the expiration of the '626 Patent in 2027. As Lupin acknowledges, "If the status quo is maintained on any appeal, because of the compound patents, Plaintiffs will enjoy continued market exclusivity until June 17, 2026." (D.I. 1083 at 2) Plaintiffs' request to submit additional evidence and briefing in support of its requested injunction, at this time, is also DENIED. It would not be a wise use of judicial resources to take more evidence and review more briefing to decide an issue that cannot become ripe for at least several years, particularly when one or more parties (including Plaintiffs and Lupin) may be prepared to pursue their appellate options. ORDERED by Judge Leonard P. Stark on 10/28/21. (ntl) |
Filing 1088 REDACTED VERSION of #1084 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc.. (Dellinger, Megan) |
Filing 1087 Letter to The Honorable Leonard P. Stark from James M. Lennon regarding response re: injunctive relief - re 1082 Order,,,, #1084 Letter. (Lennon, James) |
Filing 1086 Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding Lupin dispute - re 1082 Order,,,, #1083 Letter. (Blumenfeld, Jack) |
Filing 1085 PROPOSED ORDER -- Final Judgment -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1084 [SEALED] Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding Lupin dispute - re 1082 Order,,,,. (Blumenfeld, Jack) |
Filing 1083 Letter to The Honorable Leonard P. Stark from James M. Lennon regarding Injunctive Relief - re 1082 Order,,,,. (Lennon, James) |
Filing 1082 CORRECTED ORAL ORDER (Replacing D.I. 1081): Having reviewed the parties' joint letter of October 7 (D.I. 1080), IT IS HEREBY ORDERED that: (i) no later than Tuesday, October 19, the parties shall submit a proposed final judgment consistent with the Court's September 30 opinion, clearly marked to show any points of disagreement; (ii) also no later than October 19, any party may submit a letter, not to exceed three pages, addressing any points of disagreement in the proposed final judgment; and (iii) any party may, no later than October 20, file a responsive letter, not to exceed two pages, further addressing the points of disagreement in the proposed final judgment. IT IS FURTHER ORDERED that, on the same schedule and in letters (separate from the letters noted above) of the same maximum lengths as ordered above (i.e., 3 pages per side on October 19 and 2 pages per side on October 20), both Plaintiffs and Lupin shall file letters addressing their dispute identified in paragraph 2 of the October 7 letter. ORDERED by Judge Leonard P. Stark on 10/14/21. (ntl) |
Filing 1081 ORAL ORDER: Having reviewed the parties' joint letter of October 7 (D.I. 1080), IT IS HEREBY ORDERED that: (i) no later than Tuesday, October 20, the parties shall submit a proposed final judgment consistent with the Court's September 30 opinion, clearly marked to show any points of disagreement; (ii) also no later than October 20, any party may submit a letter, not to exceed three pages, addressing any points of disagreement in the proposed final judgment; and (iii) any party may, no later than October 21, file a responsive letter, not to exceed two pages, further addressing the points of disagreement in the proposed final judgment. IT IS FURTHER ORDERED that, on the same schedule and in letters (separate from the letters noted above) of the same maximum lengths as ordered above (i.e., 3 pages per side on October 20 and 2 pages per side on October 21), both Plaintiffs and Lupin shall file letters addressing their dispute identified in paragraph 2 of the October 7 letter. ORDERED by Judge Leonard P. Stark on 10/14/21. (ntl) |
Filing 1080 Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding status report - re #1076 Order. (Blumenfeld, Jack) |
Filing 1079 NOTICE of Withdrawal of Evan T. Sumner as Counel by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited (Pedi, Nicole) |
Filing 1078 REDACTED PUBLIC VERSION of #1075 Opinion. (ntl) |
Filing 1077 [SEALED] RESPONSE to Order re #1076 Order, #1075 Opinion Defendant Lupin's Unopposed Memorandum in Support of Redaction to Portions of the Court's September 30, 2021 Opinion filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B)(Lennon, James) |
Filing 1076 ORDER re #1075 Opinion regarding bench trial decision. Signed by Judge Leonard P. Stark on 9/30/21. (ntl) |
Filing 1075 [SEALED] OPINION re bench trial decision. Signed by Judge Leonard P. Stark on 9/30/21. This Opinion has been emailed to local counsel. (ntl) |
Filing 1074 NOTICE requesting Clerk to remove Alaina Whitt as co-counsel. Reason for request: No longer with firm. (Dellinger, Megan) |
Filing 1073 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Defendants' August 12, 2021 Letter. (Dellinger, Megan) |
Filing 1072 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding August 5, 2021 decision. (Gattuso, Dominick) |
Filing 1071 NOTICE of Change of Firm Affiliation by Lek Pharmaceuticals D.D., Sandoz Inc. Laura A. Lydigsen, Mark H. Remus, Jason W. Schigelone and Jieun Lee should be served at CROWELL & MORING (Gattuso, Dominick) |
Filing 1070 Exhibit List -- Parties' Joint List of the Admitted Exhibits -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1069 NOTICE of Lodging of Defendants Demonstrative Exhibits used at the bench trial by Lek Pharmaceuticals D.D., Sandoz Inc. (Gattuso, Dominick) |
Filing 1068 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Defendants' April 21, 2021 Letter. (Attachments: #1 Exhibit A-B)(Dellinger, Megan) |
Filing 1067 REDACTED VERSION of #1057 POST Trial Brief, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1066 REDACTED VERSION of #1056 Statement, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1065 Letter to Chief Judge Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Opposing Plaintiffs' Request to Strike DTX 1138 as Set Forth in Plaintiffs' Post-Trial Reply Brief - re #1054 POST Trial Brief,. (Gattuso, Dominick) |
Filing 1064 REDACTED VERSION of #1053 Amended Document by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 1063 REDACTED VERSION of #1052 POST Trial Brief, by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 1062 REDACTED VERSION of #1054 POST Trial Brief, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1061 Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Hyperlinked Post-Trial Briefs. (Phillips, John) |
Filing 1060 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Hyperlinked Post Trial Briefs. (Dellinger, Megan) |
Filing 1059 POST TRIAL BRIEF -- (Corrected) Plaintiffs' Post Trial Brief on Validity (D.I. 1045) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1058 STATEMENT re #1044 Proposed Findings of Fact (Corrected) Findings of Fact on Validity by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1057 [SEALED] POST TRIAL BRIEF -- (Corrected) Plaintiffs' Opening Post Trial Brief on Infringement (D.I. 1013) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1056 [SEALED] STATEMENT re #1012 Proposed Findings of Fact (Corrected) Findings of Fact on Infringement by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1055 NOTICE requesting Clerk to remove Stephen F. Raiola as co-counsel.. (Dellinger, Megan) |
Filing 1054 [SEALED] POST TRIAL BRIEF [Plaintiffs' Reply Post Trial Brief on Infringement] by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1053 [SEALED] AMENDED DOCUMENT by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. Amendment to #1046 Proposed Findings of Fact (Corrected). (Haney, Megan) |
Filing 1052 [SEALED] POST TRIAL BRIEF Defendants' Reply Post-Trial Brief on the Invalidity of the Asserted Claims of U.S. Patent Nos. 7,144,884, 8,476,279, 9,090,575, 9,125,910 and 9,278,096 by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
SO ORDERED, re #1049 STIPULATION TO EXTEND TIME Deadline for defendants to file redacted versions of Defendants' Post Trial Proposed Findings of Fact on Non-Infringement and Defendants' Post-Trial Brief on Non-Infringement to April 6, 2021 filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 4/6/21. (ntl) |
Filing 1051 REDACTED VERSION of #1046 Proposed Findings of Fact by Sigmapharm Laboratories LLC. (Haney, Megan) |
Filing 1050 REDACTED VERSION of #1047 POST Trial Brief by Sigmapharm Laboratories LLC. (Haney, Megan) |
Filing 1049 STIPULATION TO EXTEND TIME Deadline for defendants to file redacted versions of Defendants' Post Trial Proposed Findings of Fact on Non-Infringement and Defendants' Post-Trial Brief on Non-Infringement to April 6, 2021 - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 1048 STATEMENT -- Parties' Joint Errata Sheets for Trial Transcripts January 15-January 28, 2021 -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1047 [SEALED] POST TRIAL BRIEF Defendants' Post-Trial Brief on Non-Infringement by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 1046 [SEALED] Proposed Findings of Fact by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 1045 POST TRIAL BRIEF [Plaintiffs' Post Trial Brief on Validity] by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1044 Proposed Findings of Fact by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1043 Official Transcript of Case Management Conference held on June 19, 2018 before Chief Judge Leonard P. Stark. Court Reporter/Transcriber Stacy Ingram of Hawkins Reporting, phone (302) 658-6697. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/16/2021. Redacted Transcript Deadline set for 4/26/2021. Release of Transcript Restriction set for 6/24/2021. (bpg) |
Filing 1042 REDACTED VERSION of #1012 Proposed Findings of Fact by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1041 REDACTED VERSION of #1013 POST Trial Brief by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
SO ORDERED, re #1040 STIPULATION TO EXTEND TIME for Plaintiffs to file redacted versions of Plaintiffs' Proposed Findings of Fact and Opening Post-Trial Brief to March 15, 2021 filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 3/15/21. (ntl) |
Filing 1040 STIPULATION TO EXTEND TIME for Plaintiffs to file redacted versions of Plaintiffs' Proposed Findings of Fact and Opening Post-Trial Brief to March 15, 2021 - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 1039 Official Transcript of Bench Trial - Volume I held on January 28, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg) |
Filing 1038 [SEALED] Transcript of Bench Trial - Volume H held on January 27, 2021 before Chief Judge Leonard P. Stark. (bpg) |
Filing 1037 Official Transcript of Bench Trial - Volume H held on January 27, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg) |
Filing 1036 [SEALED] Transcript of Bench Trial - Volume G held on January 26, 2021 before Chief Judge Leonard P. Stark. (bpg) |
Filing 1035 Official Transcript of Bench Trial - Volume G held on January 26, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg) |
Filing 1034 [SEALED] Transcript of Bench Trial - Volume F held on January 25, 2021 before Chief Judge Leonard P. Stark. (bpg) |
Filing 1033 [SEALED] Transcript of Bench Trial - Volume F held on January 25, 2021 before Chief Judge Leonard P. Stark. Lundbeck and Sigmapharm sealed transcript. (bpg) |
Filing 1032 Official Transcript of Bench Trial - Volume F held on January 25, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg) |
Filing 1031 Official Transcript of Bench Trial - Volume E held on January 22, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg) |
Filing 1030 [SEALED] Transcript of Bench Trial - Volume D held on January 21, 2021 before Chief Judge Leonard P. Stark. (bpg) |
Filing 1029 [SEALED] Transcript of Bench Trial - Volume D held on January 21, 2021 before Chief Judge Leonard P. Stark. Lundbeck and Sigmapharm sealed transcript. (bpg) |
Filing 1028 Official Transcript of Bench Trial - Volume D held on January 21, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021.(bpg) |
Filing 1027 [SEALED] Transcript of Bench Trial - Volume C held on January 20, 2021 before Chief Judge Leonard P. Stark. (bpg) |
Filing 1026 [SEALED] Transcript of Bench Trial - Volume C held on January 20, 2021 before Judge Chief Judge Leonard P. Stark. Lundbeck and Sigmapharm sealed transcript. (bpg) |
Filing 1025 Official Transcript of Bench Trial - Volume C held on January 20, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021.(bpg) |
Filing 1024 [SEALED] Transcript of Bench Trial - Volume B held on January 19, 2021 before Chief Judge Leonard P. Stark.(bpg) |
Filing 1023 Official Transcript of Bench Trial - Volume B held on January 19, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg) |
Filing 1022 [SEALED] Transcript of Bench Trial - Volume A held on January 15, 2021 before Judge Chief Leonard P. Stark. (bpg) |
Filing 1021 Official Transcript of Bench Trial - Volume A held on January 15, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021.(bpg) |
Filing 1020 Official Transcript of Pretrial Conference held on January 8, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg) |
Filing 1019 Redaction of #1004 Transcript. Telephone Conference held on February 10, 2021.(bpg) |
Filing 1018 REDACTED VERSION of #1010 Proposed Findings of Fact by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 1017 REDACTED VERSION of #1011 POST Trial Brief by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 1016 REDACTED VERSION of #1009 MOTION to Redact #1004 Transcript,, (Unopposed) by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Proposed Order)(Haney, Megan) |
Filing 1015 ORDER re #1009 MOTION to Redact #1004 Transcript (Unopposed) filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 3/9/21. (ntl) |
Filing 1014 NOTICE of Lodging of demonstrative exhibits used at bench trial by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. (Dellinger, Megan) |
Filing 1013 [SEALED] POST TRIAL BRIEF by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1012 [SEALED] Proposed Findings of Fact by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1011 [SEALED] POST TRIAL BRIEF Defendants' Opening Post-Trial Brief on Invalidity by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 1010 [SEALED] Proposed Findings of Fact by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 1009 [SEALED] MOTION to Redact #1004 Transcript,, (Unopposed) - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Proposed Order)(Haney, Megan) |
Filing 1008 REDACTED VERSION of #1005 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1)(Dellinger, Megan) |
Filing 1007 REDACTED VERSION of #1001 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 1006 ORAL ORDER: Having reviewed the parties' February 12 letter (D.I. 1005), IT IS HEREBY ORDERED that Plaintiffs' proposal for post-trial submissions as set out in that letter (id. at 2) is ADOPTED. IT IS FURTHER ORDERED that no later than April 16 the parties shall submit electronic versions of all briefs with hyperlinks to all exhibits. ORDERED by Judge Leonard P. Stark on 2/15/21. (ntl) |
Filing 1005 [SEALED] Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding Post-Trial Briefing. (Attachments: #1 Exhibit 1)(Blumenfeld, Jack) |
Filing 1004 [SEALED] Official Transcript of Telephone Conference held on February 10, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. (bpg) Modified on 3/9/2021 (ntl). |
Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 2/10/2021. (Court Reporter B. Gaffigan.) (ntl) |
Filing 1003 Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Post-Trial Briefing - re #1001 Letter, 1000 Order,,,,,,,. (Attachments: #1 Exhibit 1)(Phillips, John) |
Filing 1002 ORAL ORDER: Having reviewed today's letter from Plaintiffs (D.I. 1001), and understanding that Defendants evidently do not oppose the briefing schedule and page limits ordered yesterday by the Court (D.I. 1000), IT IS HEREBY ORDERED that the Court will hold a status teleconference tomorrow, February 10, at 3pm to discuss with the parties whether the Court should modify the schedule and page limits it has set out and to address how and when issues relating to invalidity will be briefed. The parties can access the teleconference by dialing 877-336-1829 and using the access code 1408971. ORDERED by Judge Leonard P. Stark on 2/9/21. (ntl) |
Filing 1001 [SEALED] Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding post-trial briefing - re 1000 Order,,,,,,,. (Attachments: #1 Exhibits 1-2)(Blumenfeld, Jack) |
Filing 1000 ORAL ORDER: Having reviewed the parties' letter regarding the post-trial briefing schedule (D.I. 999), which appears to contemplate in excess of 500 pages of briefing and an additional almost 500 pages of proposed findings of fact, having further considered that the parties propose to take three months to complete briefing and have made no proposal (to date) "regarding potential launches discussed at the conclusion of the trial" (id. at 2), and considering the Court's schedule and other commitments as well as its detailed familiarity with the extensive record created at the recent trial, IT IS HEREBY ORDERED that the parties' proposal is REJECTED. Instead, IT IS FURTHER ORDERED that the following page limits and schedule shall apply: (i) on infringement, Plaintiffs' opening briefing of no more than 100 pages and findings of fact of no more than 100 pages are due on February 23; (ii) on infringement, answering briefing of no more than 100 pages (in total, adding up all Defendants' briefs) and findings of fact of no more than 100 pages (in total, adding up all Defendants' proposals) are due on March 16, 2021; and (iii) on infringement, Plaintiffs' reply briefing of no more than 50 pages is due on March 26. Briefing on invalidity will proceed according to a separate schedule with separate page limits after the Court receives further input from the parties. Any party that strenuously objects to this Order shall, no later than 12:00 p.m. tomorrow, February 9, submit a short letter brief requesting reconsideration and including a proposal more reasonable than the one the Court has today rejected. In the absence of any such request, the Court will adhere to this Order and, in that instance, the parties are further directed to submit (by no later than February 10) a revised proposal(s) for briefing the invalidity issues. ORDERED by Judge Leonard P. Stark on 2/8/21. (ntl) |
Filing 999 Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding post-trial briefing schedule. (Blumenfeld, Jack) |
Filing 998 Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding status report. (Phillips, John) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial completed on 1/28/2021. (Court Reporter B. Gaffigan.) (ntl) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/27/2021. (Court Reporter B. Gaffigan.) (ntl) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/26/2021. (Court Reporter B. Gaffigan.) (ntl) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/25/2021. (Court Reporter B. Gaffigan.) (ntl) |
SO ORDERED, re #996 MOTION for Pro Hac Vice Appearance of Attorney Stephen F. Raiola filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 1/25/21. (ntl) |
Filing 997 Redaction of #959 Transcript. Transcript of discovery dispute held on September 25, 2020 before Judge Hall. (bpg) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/22/2021. (Court Reporter B. Gaffigan.) (ntl) |
Filing 996 MOTION for Pro Hac Vice Appearance of Attorney Stephen F. Raiola - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/21/2021. (Court Reporter B. Gaffigan.) (ntl) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/20/2021. (Court Reporter B. Gaffigan.) (ntl) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/19/2021. (Court Reporter B. Gaffigan.) (ntl) |
SO ORDERED, re #995 Consent Judgment -- Party MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. terminated. Attorney Matthew L. Fedowitz and Geoffrey Graham Grivner terminated. Signed by Judge Leonard P. Stark on 1/19/21. (ntl) |
Filing 995 PROPOSED CONSENT JUDGMENT by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Grivner, Geoffrey) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/15/2021. (Court Reporter B. Gaffigan.) (ntl) |
CORRECTING ENTRY: Corrected Exhibit 12 added to D.I. 988 per request of counsel. (ntl) |
Filing 994 ORAL ORDER: The Bench Trial is available to the public using the following dial-in for audio access: 703-552-8058 and the conference code is 646321. Audio reproduction of the proceeding is strictly prohibited. ORDERED by Judge Leonard P. Stark on 1/13/21. (ntl) |
Filing 993 ORAL ORDER: IT IS HEREBY ORDERED that D.I. 794 (a motion to dismiss by former defendants) is DENIED AS MOOT. (See D.I. 946). ORDERED by Judge Leonard P. Stark on 1/8/21. (ntl) |
Filing 992 ORDER re #963 MOTION to Redact #959 Transcript Portions of the September 25, 2020 Discovery Dispute Teleconference Transcript (Unopposed) filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 1/8/21. (ntl) |
Filing 991 MEMORANDUM ORDER re #908 Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Complaint and To Dismiss For Lack Of Subject Matter Jurisdiction filed by Lek Pharmaceuticals D.D., Sandoz Inc. Signed by Judge Leonard P. Stark on 1/8/21. (ntl) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Pretrial Conference held on 1/8/2021. (Court Reporter B. Gaffigan.) (ntl) |
Filing 990 MEMORANDUM ORDER regarding the Court's decisions on motions in limine, pretrial order issues, and other trial related matters. Signed by Judge Leonard P. Stark on 1/7/21. (ntl) |
CORRECTING ENTRY: Attachment 1 of DI 988 replaced with corrected version at the request of counsel. (etg) |
Filing 989 Letter of Request to the Ministry of Justice, Paris, France. Signed by Judge Leonard P. Stark on 12/31/20. (ntl) |
SO ORDERED, re #980 MOTION for Pro Hac Vice Appearance of Attorney Brian Sodikoff filed by Lupin Pharmaceuticals Inc., Lupin Limited. Signed by Judge Leonard P. Stark on 1/5/21. (ntl) |
SO ORDERED, re #983 PROPOSED CONSENT JUDGMENT as to Alkem Laboratories Ltd. Party Alkem Laboratories Ltd. terminated. Attorney Kendall K. Gurule; Pilar Gabrielle Kraman; Adam Wyatt Poff; Tedd W. Van Buskirk; Aaron S. Eckenthal and Russell W. Faegenburg terminated. Signed by Judge Leonard P. Stark on 1/4/21. (ntl) |
Filing 988 [SEALED] Proposed Pretrial Order (Volume 4 of 4 -- Exhibits 12-14) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 12-14)(Dellinger, Megan) (Attachment 1 replaced on 1/7/2021) (etg). (Attachment 1 replaced on 1/15/2021) (ntl). |
Filing 987 [SEALED] Proposed Pretrial Order (Volume 3 of 4 -- Exhibits 3-11) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 3-11)(Dellinger, Megan) |
Filing 986 [SEALED] Proposed Pretrial Order (Volume 2 of 4 -- Exhibits 2-2J) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 2-2J)(Dellinger, Megan) |
Filing 985 [SEALED] Proposed Pretrial Order (Volume 1 of 4 -- Exhibits 1-1J) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-1J)(Dellinger, Megan) |
Filing 984 NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.'s Supplemental Objections and Responses to Plaintiffs' Requests for Admissions Nos. 12-16 and Nos. 27-28 [HIGHLY CONFIDENTIAL-SUBJECT TO PROTECTIVE ORDER] filed by Lek Pharmaceuticals D.D., Sandoz Inc..(Gattuso, Dominick) |
Filing 983 PROPOSED CONSENT JUDGMENT as to Alkem Laboratories Ltd. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack) |
Filing 982 Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Response to Oral Order - re 979 Order. (Phillips, John) |
Filing 981 Letter to The Honorable Chief Judge Leonard P. Stark from Renee Mosley Delcollo regarding Court's Oral Order dated December 29, 2020 [D.I. 979] - re 979 Order. (Delcollo, Renee) |
Filing 980 MOTION for Pro Hac Vice Appearance of Attorney Brian Sodikoff - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) |
Pro Hac Vice Attorney Matthew M. Kamps for Sigmapharm Laboratories LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
Filing 979 ORAL ORDER: IT IS HEREBY ORDERED that Defendants shall file a letter response indicating their position on the Plaintiffs' #978 letter of request by no later than 4:00 pm tomorrow. ORDERED by Judge Leonard P. Stark on 12/29/20. (ntl) |
Filing 978 Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding expert testimony. (Attachments: #1 proposed Letter of Request)(Blumenfeld, Jack) |
Filing 977 ORAL ORDER: IT IS HEREBY ORDERED that, for reasons discussed during the December 9, 2020 teleconference, and having reviewed the parties' joint status report (D.I. 975), the bench trial in this matter is RESCHEDULED and will be held on some or all of the following dates, subject to the parties' time limits: January 15-29, 2021. The pretrial conference will be held on January 8, 2021 at 2:30 p.m. and the proposed pretrial order is due on January 4, 2021. ORDERED by Judge Leonard P. Stark on 12/14/20. (ntl) |
Filing 976 Official Transcript of Telephone Conference held on December 9, 2020 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/4/2021. Redacted Transcript Deadline set for 1/11/2021. Release of Transcript Restriction set for 3/11/2021.(bpg) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 12/9/2020. (Court Reporter B. Gaffigan.) (ntl) |
Filing 975 Joint STATUS REPORT by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack) |
Filing 974 ORAL ORDER: IT IS HEREBY ORDERED that a status teleconference is scheduled for December 9, 2020 at 4:30 p.m. The parties can access the teleconference by dialing 877-336-1829 and using the access code 1408971. IT IS FURTHER ORDERED that the parties shall submit a joint status report on December 8, 2020. ORDERED by Judge Leonard P. Stark on 12/7/2020. (ntl) |
Filing 973 NOTICE OF SERVICE of Defendants' Notice of Prior Art Under 35 U.S.C. 282 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Pro Hac Vice Attorney Kendall K. Gurule for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
Filing 972 MOTION for Pro Hac Vice Appearance of Attorney Kendall K. Gurule - filed by Alkem Laboratories Ltd.. (Kraman, Pilar) |
Pro Hac Vice Attorney Jonathan B. Turpin for Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
SO ORDERED, re #972 MOTION for Pro Hac Vice Appearance of Attorney Kendall K. Gurule filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 12/1/20. (ntl) |
Pro Hac Vice Attorney Stephen R. Howe for Sigmapharm Laboratories LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
Pro Hac Vice Attorney August Melcher for Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
Filing 971 MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Howe and Matthew M. Kamps - filed by Sigmapharm Laboratories LLC. (Attachments: #1 Certification of Stephen R. Howe, #2 Certification of Matthew M. Kamps)(Haney, Megan) |
SO ORDERED, re #969 Consent Judgment -- Party Torrent Pharma Inc., Torrent Pharmaceuticals Limited terminated. Attorney Alton L. Hare, III; Brandon Ryan Harper; Stephanie S. Riley; Hemant Keeto Sabharwal; Cedric C. Y. Tan; Yun Wei; Ahmed Abdel-Rahman and Arthur G. Connolly, III terminated. Signed by Judge Leonard P. Stark on 11/23/20. (ntl) |
SO ORDERED, re #971 MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Howe and Matthew M. Kamps filed by Sigmapharm Laboratories LLC, #970 MOTION for Pro Hac Vice Appearance of Attorney Jonathan B. Turpin and August Melcher filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 11/23/20. (ntl) |
Filing 970 MOTION for Pro Hac Vice Appearance of Attorney Jonathan B. Turpin and August Melcher - filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Turpin Pro Hac Certification, #2 Melcher Pro Hac Certification)(Haney, Megan) |
Filing 969 PROPOSED CONSENT JUDGMENT between Lundbeck and Takeda and Torrent by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Harper, Brandon) |
Filing 968 NOTICE to Take Deposition of Allan S. Myerson, Ph.D. on November 13, 2020 filed by Sigmapharm Laboratories LLC.(Phillips, John) |
Filing 967 NOTICE to Take Deposition of Dr. Allan S. Myerson on November 16, 2020 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 966 NOTICE to Take Deposition of Dr. Allan S. Myerson on November 13, 2020 beginning at 12:00 p.m. filed by Alkem Laboratories Ltd..(Kraman, Pilar) |
Filing 965 NOTICE to Take Deposition of Allan S. Myerson on November 12, 2020 filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 964 REDACTED VERSION of #963 MOTION to Redact #959 Transcript Portions of the September 25, 2020 Discovery Dispute Teleconference Transcript (Unopposed) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-B)(Dellinger, Megan) |
Filing 963 [SEALED] MOTION to Redact #959 Transcript Portions of the September 25, 2020 Discovery Dispute Teleconference Transcript (Unopposed) - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Text of Proposed Order)(Dellinger, Megan) |
Filing 962 REDACTED VERSION of #961 Stipulation and Proposed Order Regarding Evidentiary Treatment by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Harper, Brandon) |
SO ORDERED, re #961 STIPULATION and Order Regarding Evidentiary Treatment filed by Torrent Pharmaceuticals Limited, Torrent Pharma Inc.. Signed by Judge Leonard P. Stark on 10/23/20. (ntl) |
Filing 961 [SEALED] STIPULATION Regarding Evidentiary Treatment by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Harper, Brandon) |
Filing 960 NOTICE of Intent to Request Redaction by Megan Elizabeth Dellinger re #959 Transcript. (Dellinger, Megan) |
SO ORDERED, re #958 STIPULATION of Dismissal (Partially) Dismissing without Prejudice Counts VII and VIII of Plaintiffs' Third Amended Complaint and Defendant Sandoz Inc.'s Eleventh and Twelfth Counterclaims. Signed by Judge Leonard P. Stark on 10/5/20. (ntl) |
Filing 959 [SEALED] Transcript of discovery dispute held on September 25, 2020 before Judge Hall.. (vjg) |
SO ORDERED, re #955 STIPULATION and [Proposed] Order Permitting Expert Depositions Outside of Discovery Period. Signed by Judge Leonard P. Stark on 10/5/20. (ntl) |
Filing 958 STIPULATION of Dismissal (Partially) Dismissing without Prejudice Counts VII and VIII of Plaintiffs' Third Amended Complaint and Defendant Sandoz Inc.'s Eleventh and Twelfth Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 957 REDACTED VERSION of #952 Letter,, regarding response to Plaintiff discovery dispute letter by Sandoz Inc.. (Attachments: #1 Exhibit 1-4, #2 Exhibit 5, #3 Exhibit 6)(Gattuso, Dominick) |
Filing 956 ORAL ORDER: IT IS HEREBY ORDERED that the transcript of the September 25, 2020 discovery dispute teleconference shall serve as the Order of the Court. ORDERED by Judge Jennifer L. Hall on 9/25/2020. (ceg) |
Filing 955 STIPULATION and [Proposed] Order Permitting Expert Depositions Outside of Discovery Period by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute Teleconference held on 9/25/2020. (*Court Reporter Valerie Gunning.) (ceg) |
SO ORDERED, re #946 Consent Judgment -- Party Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. terminated. Attorney Steven J. Fineman; Yixin H. Tang; Shashank D. Upadhye; Brent A. Batzer and Tyler E. Cragg terminated. Signed by Judge Leonard P. Stark on 9/18/20. (ntl) |
Filing 954 NOTICE of Withdrawal of Certain Pro Hac Counsel by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited (Grivner, Geoffrey) |
Filing 953 REDACTED VERSION of #947 Letter, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 952 [SEALED] Letter to The Honorable Jennifer L. Hall from Dominick T. Gattuso, Esq. regarding Response to Plaintiffs Discovery Dispute Letter - re 941 Order Setting Teleconference,,,, #938 Joint MOTION for Teleconference to Resolve Discovery Disputes between Plaintiffs and Sandoz Inc. & Lek Pharmaceuticals d.d.. (Attachments: #1 Exhibit (CONFIDENTIAL) EX 1 to Letter, #2 Exhibit (CONFIDENTIAL EX 2 to Letter, #3 Exhibit (CONFIDENTIAL) EX 3 to Letter, #4 Exhibit (CONFIDENTIAL) EX 4 to Letter, #5 Exhibit (CONFIDENTIAL) EX 5 to Letter, #6 Exhibit (CONFIDENTIAL) EX 6 to Letter, #7 Certificate of Service to Letter)(Gattuso, Dominick) |
Filing 951 NOTICE to Take Deposition of Mendy M. Gould on September 25, 2020, beginning at 9:00 a.m. filed by Alkem Laboratories Ltd..(Kraman, Pilar) |
Filing 950 NOTICE to Take Deposition of Mendy M. Gould on September 25, 2020 filed by Sigmapharm Laboratories LLC.(Haney, Megan) |
Filing 949 NOTICE to Take Deposition of Roger S. McIntyre, M.D. on September 19, 2020 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 948 REDACTED VERSION of #944 Reply to Response to Motion, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 947 [SEALED] Letter to The Honorable Jennifer L. Hall from Jack B. Blumenfeld regarding discovery dispute with Sandoz - re 941 Order Setting Teleconference,,,, #938 Joint MOTION for Teleconference to Resolve Discovery Disputes between Plaintiffs and Sandoz Inc. & Lek Pharmaceuticals d.d.. (Attachments: #1 Exhibits A-H)(Blumenfeld, Jack) |
Filing 946 PROPOSED CONSENT JUDGMENT by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack) |
Filing 945 NOTICE to Take Deposition of Mickael Morin, Ph.D. on September 16, 2020 filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
Filing 944 [SEALED] REPLY to Response to Motion re #908 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Opening Brief in Support of Their Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Com MOTION for Judgment on the Pleadings filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 943 REDACTED VERSION of #938 Joint MOTION for Teleconference to Resolve Discovery Disputes between Plaintiffs and Sandoz Inc. & Lek Pharmaceuticals d.d. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 942 REDACTED VERSION of #937 Response to Motion,, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 941 ORAL ORDER Setting Teleconference: The Court has reviewed the Joint Motion for Teleconference to Resolve Discovery Disputes (D.I. #938 ). A discovery dispute teleconference is scheduled for September 25, 2020 at 2:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than September 15, 2020 the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than September 22, 2020, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Jennifer L. Hall on 9/8/2020. (ceg) |
Filing 940 REDACTED VERSION of #934 Stipulation, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Letter to the Court)(Delcollo, Renee) |
Filing 939 NOTICE of Defendants' Notice of Deposition of Dr. Carl C. Peck, M.D. by Lek Pharmaceuticals D.D., Sandoz Inc. (Gattuso, Dominick) |
Filing 938 [SEALED] Joint MOTION for Teleconference to Resolve Discovery Disputes between Plaintiffs and Sandoz Inc. & Lek Pharmaceuticals d.d. - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 937 [SEALED] RESPONSE to Motion re #908 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Opening Brief in Support of Their Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Com MOTION for Judgment on the Pleadings filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 936 NOTICE to Take Deposition of Fabia Gozzo on September 3, 2020 filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Harper, Brandon) |
Filing 935 NOTICE to Take Deposition of Fabia Gozzo on September 3, 2020 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey) |
SO ORDERED, re #934 [SEALED] STIPULATION and [Proposed] Order filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 9/1/20. (ntl) |
Filing 934 [SEALED] STIPULATION and [Proposed] Order by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Letter to The Honorable Chief Judge Leonard P. Stark from Renee Mosley Delcollo regarding enclosed Stipulation and Proposed Order)(Delcollo, Renee) |
Filing 933 NOTICE OF SERVICE of Expert Report of Dr. Carl C. Peck, M.D. in Reply to the Rebuttal Expert Report of Dr. Peter Rheinstein filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 932 NOTICE to Take Deposition of Grace Kim on September 11, 2020 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 931 NOTICE to Take Deposition of Dr. Jacques Ledru on September 11, 2020 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 930 NOTICE to Take Deposition of Brianne Bharkhda on September 11, 2020 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 929 NOTICE to Take Deposition of Dr. Paul Reider on August 31, 2020 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 928 REDACTED VERSION of #910 Declaration,, #911 Declaration, Declaration of Jieun Lee In Support of Defendants Lek Pharmaceuticals d.d. and Sandoz Inc.'s Motion to Dismiss by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Exhibits A-I, #2 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 927 REDACTED VERSION of #909 Opening Brief in Support,, Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Opening Brief in Support of Their Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Complaint and To Dismiss For Lack Of Subject Matter Jurisdiction by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 926 REDACTED VERSION of #904 Letter,, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Exhibit A-D)(Delcollo, Renee) |
Filing 925 REDACTED VERSION of #903 SEALED MOTION to Enforce This Court's Prior Order (D.I. 801) and Renewed Motion to Strike Plaintiffs' Untimely Infringement Contentions (D.I. 749) re 801 Oral Order,,,,,,,,,,,,,, #749 MOTION to Strike Plaintiffs' Untimely I by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Text of Proposed Order Proposed Order)(Delcollo, Renee) |
Filing 924 REDACTED VERSION of #906 Letter, by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) |
Filing 923 REDACTED VERSION of #900 Letter, by Lupin Limited, Lupin Pharmaceuticals Inc.. (Attachments: #1 Exhibit 1-2)(Lennon, James) |
Filing 922 REDACTED VERSION of #899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747) by Lupin Limited, Lupin Pharmaceuticals Inc.. (Attachments: #1 Exhibit D-E)(Lennon, James) |
Filing 921 REDACTED VERSION of #905 Letter,, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 920 NOTICE to Take Deposition of Dr. Gregory M. Mattingly on August 26, 2020 filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 919 NOTICE of change of State of Incorporation by Lek Pharmaceuticals D.D., Sandoz Inc. (Gattuso, Dominick) |
Filing 918 NOTICE to Take Deposition of Grace Kim on September 3, 2020 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Phillips, John) |
Filing 917 NOTICE to Take Deposition of Jacques Ledru on September 2, 2020 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Phillips, John) |
Filing 916 NOTICE to Take Deposition of Brianne Bharkhda on September 1, 2020 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Phillips, John) |
Filing 915 REDACTED PUBLIC VERSION of #912 [SEALED] ORDER re 899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747) filed by Lupin Pharmaceuticals Inc., Lupin Limited is GRANTED. Signed by Judge Leonard P. Stark on 8/20/20. (etg) |
Filing 914 NOTICE of Appearance by Brandon Ryan Harper on behalf of Torrent Pharma Inc., Torrent Pharmaceuticals Limited (Harper, Brandon) |
Filing 913 NOTICE to Take Deposition of Christopher A. Vellturo on August 25, 2020 filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 912 [SEALED] ORDER re #899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747)filed by Lupin Pharmaceuticals Inc., Lupin Limited is GRANTED. Signed by Judge Leonard P. Stark on 8/20/20. This order has been emailed to local counsel. (ntl) |
CORRECTING ENTRY: Corrected document added to D.I. 907 per request of counsel. (ntl) |
CORRECTING ENTRY: Text from DI #908 Modified per Counsels Request. (apk) |
Filing 911 [SEALED] DECLARATION re #910 Declaration,, Declaration of Jieun Lee In Support of Defendants Lek Pharmaceuticals d.d. and Sandoz Inc.'s Motion to Dismiss by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit I, #2 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 910 [SEALED] DECLARATION re #908 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Opening Brief in Support of Their Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Com MOTION for Judgment on the Pleadings Declaration of Jieun Lee In Support of Defendants Lek Pharmaceuticals d.d. and Sandoz Inc.'s Motion to Dismiss by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit A-H, #2 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 909 [SEALED] OPENING BRIEF in Support re #908 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Opening Brief in Support of Their Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Com MOTION for Judgment on the Pleadings filed by Lek Pharmaceuticals D.D., Sandoz Inc..Answering Brief/Response due date per Local Rules is 9/2/2020. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 908 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Complaint and To Dismiss For Lack Of Subject Matter Jurisdiction [With Proposed Order], MOTION for Judgment on the Pleadings - filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Gattuso, Dominick) Modified on 8/20/2020 (apk). |
Filing 907 NOTICE to Take Deposition of Dr. David MacMillan on August 21, 2020 filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) (Main Document 907 replaced on 8/20/2020) (ntl). |
Filing 906 [SEALED] Letter to The Honorable Leonard P. Stark from James M. Lennon regarding Support of Expedited Motion to Enforce Prior Order and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports - re #900 Letter, #899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747), #748 Letter, #764 Letter,. (Lennon, James) |
Filing 905 [SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s Motion to Expedite to Enforce this Court's Prior Order and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports - re #900 Letter, #899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747). (Attachments: #1 Exhibits 1-3)(Dellinger, Megan) |
Filing 904 [SEALED] SEALED Letter to The Honorable Chief Judge Leonard P. Stark from Rene Mosley Delcollo regarding re: Motion to Enforce This Court's Prior Order and Renewed Motion to Strike - re #903 SEALED MOTION to Enforce This Court's Prior Order (D.I. 801) and Renewed Motion to Strike Plaintiffs' Untimely Infringement Contentions (D.I. 749) re 801 Oral Order,,,,,,,,,,,,,, #749 MOTION to Strike Plaintiffs' Untimely I. (Attachments: #1 Exhibit A-D)(Delcollo, Renee) |
Filing 903 [SEALED] SEALED MOTION to Enforce This Court's Prior Order (D.I. 801) and Renewed Motion to Strike Plaintiffs' Untimely Infringement Contentions (D.I. 749) re 801 Oral Order,,,,,,,,,,,,,, #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Text of Proposed Order)(Delcollo, Renee) |
Filing 902 NOTICE of Defendants' Notice of Deposition of Dr. Anita Clayton, M.D. by Lek Pharmaceuticals D.D., Sandoz Inc. (Gattuso, Dominick) (Main Document 902 replaced on 8/17/2020) (ntl). |
Filing 901 ORAL ORDER: IT IS HEREBY ORDERED that Lupin's request to expedite consideration of its renewed motion to strike is GRANTED. The Court agrees that this dispute should be resolved in advance of the forthcoming deposition. Accordingly, IT IS FURTHER ORDERED that any party opposing the relief requested by Lupin file a letter brief, not to exceed five pages, no later than tomorrow, August 18; and Lupin may file a reply letter brief, not to exceed two pages, no later than Wednesday, August 19. ORDERED by Judge Leonard P. Stark on 8/17/20. (ntl) |
CORRECTING ENTRY: Corrected document added to D.I. 902 per request of counsel. (ntl) |
CORRECTING ENTRY: Correct exhibits added to D.I. 899-900 per request of counsel. (ntl) |
Filing 900 [SEALED] Letter to The Honorable Leonard P. Stark from James M. Lennon regarding Support of Expedited Motion to Enforce and Renewed Motion to Strike - re #899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747). (Lennon, James) (Additional attachment(s) added on 8/14/2020: #1 Exhibit 1, #2 Exhibit 2) (ntl). Modified on 8/14/2020 (ntl). |
Filing 899 [SEALED] MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747) - filed by Lupin Limited, Lupin Pharmaceuticals Inc. (Attachments: #1 Exhibit D, #2 Exhibit E)(Lennon, James) (Attachment 1 replaced on 8/14/2020) (ntl). (Attachment 2 replaced on 8/14/2020) (ntl). Modified on 8/14/2020 (ntl). |
Filing 898 NOTICE OF SERVICE of Expert Report of Dr. Carl C. Peck, M.D. in Reply to the Responsive Expert Report of Anthony J. Rothschild, M.D. and the Rebuttal Expert Report of Victor I. Reus, M.D. filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 897 NOTICE of Deposition of Brianne Bharkhda by Lek Pharmaceuticals D.D., Sandoz Inc. (Gattuso, Dominick) |
Filing 896 REDACTED VERSION of #884 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 895 REDACTED VERSION of #883 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 894 REDACTED VERSION of #885 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 893 NOTICE OF SERVICE of Reply Expert Reports (served on various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 892 NOTICE OF SERVICE of Reply Expert Report of Gregory Stephenson, Ph.D. Regarding Invalidity of the Polymorph Patents filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 891 NOTICE OF SERVICE of Reply Expert Report of Dr. Salvatore Lepore filed by Sigmapharm Laboratories LLC.(Haney, Megan) |
Filing 890 NOTICE OF SERVICE of Reply Expert Report of Victor L. Reus, M.D. filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 889 NOTICE OF SERVICE of Expert Report of Jonathan W. Steed, Ph.D. in Rebuttal to the Opening Expert Report of Myerson [HIGHLY CONFIDENTIAL] filed by Lek Pharmaceuticals D.D., Sandoz Inc..(Gattuso, Dominick) |
Filing 888 NOTICE OF SERVICE of Expert Report of Dr. Peter Rheinstein in Rebuttal to the Opening Expert Report of Carl C. Peck, M.D. [HIGHLY CONFIDENTIAL] filed by Lek Pharmaceuticals D.D., Sandoz Inc..(Gattuso, Dominick) |
Filing 887 NOTICE OF SERVICE of Defendants' Reply Expert Report of Anthony J. Rothschild, M.D. filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine) |
Filing 886 ANSWER to #856 Answer to Amended Complaint, Counterclaim -- Answer to Torrent's Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 885 [SEALED] ANSWER to #854 Answer to Amended Complaint, Counterclaim -- Answer to MSN's Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 884 [SEALED] ANSWER to #850 Answer to Amended Complaint, Counterclaim -- Answer to Alkem's Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 883 [SEALED] ANSWER to #845 Answer to Amended Complaint,, Counterclaim, -- Answer to Sandoz Inc.'s Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 882 REDACTED VERSION of #867 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 881 REDACTED VERSION of #869 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 880 REDACTED VERSION of #868 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 879 [SEALED] SO ORDERED, re #860 PROPOSED CONSENT JUDGMENT between Plaintiffs and Apotex Inc., Apotex Corp., and Apotex Research Private Limited. Signed by Judge Leonard P. Stark on 7/28/20. (ntl) |
Filing 878 NOTICE of Withdrawal of Counsel by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. (Dellinger, Megan) |
SO ORDERED, re #861 STIPULATION TO EXTEND TIME for the parties to serve their reply expert reports to dates as outlined in stipulation filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #873 STIPULATION TO EXTEND TIME to file Redacted Version of Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Answer, Defenses, and Counterclaims to Plaintiffs' Second Amended Complaint for Patent Infringement (D.I. 856) to July 27, 2020 filed by Torrent Pharmaceuticals Limited, Torrent Pharma Inc. Signed by Judge Leonard P. Stark on 7/28/20. (ntl) |
Filing 877 REDACTED VERSION of #860 Proposed Consent Judgment, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 876 ORAL ORDER: Having reviewed the parties' recent letters relating to expert discovery (D.I. 858, 859, 862, 863, 864), IT IS HEREBY ORDERED that Defendants' request that the Court reconsider its July 6 Order (D.I. 829) is GRANTED to the limited extent that each defendant contesting infringement shall have a maximum of 7 additional hours (not the previously-ordered 4 additional hours) to depose Dr. Myerson and either Dr. Morin or Dr. Gozzo), as applicable, on infringement issues specific and unique to that defendant, provided that each such defendant shall notify Plaintiffs in advance of the beginning of expert depositions how many hours each defendant seeks to use with which of Drs. Myerson, Morin, and Gozzo. Reconsideration is warranted because 7 additional hours is the amount of time Plaintiffs had proposed and the Court does not intend to provide Defendants fewer hours than even Plaintiffs proposed. ORDERED by Judge Leonard P. Stark on 7/28/20. (ntl) Modified on 7/28/2020 (ntl). |
Filing 875 ORAL ORDER: Having reviewed the joint status report (D.I. 839), as well as subsequent letters of July 22 and 23, IT IS HEREBY ORDERED that Plaintiffs and/or the Sandoz Defendants may file a motion to dismiss any claims or counterclaims relating to the '910 and/or '096 patents, but the Court is not granting any relief at this time based on the status report and any limited argument that has been provided to date. ORDERED by Judge Leonard P. Stark on 7/28/20. (ntl) |
Filing 874 REDACTED VERSION of #856 Answer to Amended Complaint, Counterclaim by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Riley, Stephanie) |
SO ORDERED, re #871 STIPULATION TO EXTEND TIME to Respond to Sandoz's Counterclaims to July 31, 2020 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 7/27/20. (ntl) |
Filing 873 STIPULATION TO EXTEND TIME to file Redacted Version of Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Answer, Defenses, and Counterclaims to Plaintiffs' Second Amended Complaint for Patent Infringement (D.I. 856) to July 27, 2020 - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Riley, Stephanie) |
Filing 872 REDACTED VERSION of #854 Answer to Amended Complaint, Counterclaim by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Grivner, Geoffrey) |
Filing 871 STIPULATION TO EXTEND TIME to Respond to Sandoz's Counterclaims to July 31, 2020 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 870 ANSWER to #844 Answer to Amended Complaint, Counterclaim -- Answer to Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 869 [SEALED] ANSWER to #846 Answer to Amended Complaint, Counterclaim -- Answer to Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc.'s Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 868 [SEALED] ANSWER to #843 Answer to Amended Complaint, Counterclaim -- Answer to Prinston Pharmaceutical Inc.'s Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 867 [SEALED] ANSWER to #841 Answer to Amended Complaint, Counterclaim -- Answer to Lupin Limited's Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 866 REDACTED VERSION of #850 Answer to Amended Complaint, Counterclaim by Alkem Laboratories Ltd.. (Kraman, Pilar) |
Filing 865 REDACTED VERSION of #855 Answer to Amended Complaint by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Phillips, John) |
Filing 864 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Plaintiffs letter filed July 22, 2020 - re #863 Letter. (Gattuso, Dominick) |
Filing 863 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding depositions - re #862 Letter. (Dellinger, Megan) |
Filing 862 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esq. regarding Plaintiffs' July 20, 2020 letter - re #859 Letter. (Gattuso, Dominick) |
Filing 861 STIPULATION TO EXTEND TIME for the parties to serve their reply expert reports to dates as outlined in stipulation - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 860 [SEALED] PROPOSED CONSENT JUDGMENT between Plaintiffs and Apotex Inc., Apotex Corp., and Apotex Research Private Limited by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 859 Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding defendants' request for more deposition hours - re #858 Letter. (Blumenfeld, Jack) |
Filing 858 Letter to the Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Clarification of July 6, 2020 Oral Order - re 829 Order,,,,,,,,,,,, Set Deadlines/Hearings,,,,,,,,,,,. (Phillips, John) |
Filing 857 REDACTED VERSION of #846 Answer to Amended Complaint, Counterclaim to Third Amended Complaint by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Farnan, Kelly) |
Filing 856 [SEALED] ANSWER to Amended Complaint, re: #811 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Attachments: #1 Certificate of Service)(Riley, Stephanie) |
Filing 855 [SEALED] ANSWER to Amended Complaint, re: #812 Amended Complaint, Affirmative Defenses by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Phillips, John) |
Filing 854 [SEALED] ANSWER to Amended Complaint, re: #807 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey) |
Filing 853 REDACTED VERSION of #841 Answer to Amended Complaint, Counterclaim by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) |
Filing 852 REDACTED VERSION of #843 Answer to Amended Complaint, Counterclaim by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Cragg, Tyler) |
Filing 851 REDACTED VERSION of #842 Answer to Amended Complaint, Counterclaim by Apotex Corp., Apotex Inc.. (Dorsney, Kenneth) |
Filing 850 [SEALED] ANSWER to Amended Complaint, re: #803 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Alkem Laboratories Ltd..(Kraman, Pilar) |
Filing 849 REDACTED VERSION of #845 Answer to Amended Complaint,, Counterclaim, Defendants Answer and Affirmative Defenses and Sandoz's Counterclaims to the Third Amended Complaint for Patent Infringement, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 848 ANSWER to #831 Answer to Amended Complaint, Counterclaim -- Answer to Sigmapharm Laboratories, LLC's Counterclaims to Second Amended Complaint -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 847 REDACTED VERSION of #839 Status Report, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 846 [SEALED] ANSWER to Amended Complaint, re: #806 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 845 [SEALED] ANSWER to Amended Complaint, re: #809 Amended Complaint, with Jury Demand Defendants Answer and Affirmative Defenses and Sandozs Counterclaims to the Third Amended Complaint for Patent Infringement, COUNTERCLAIM against All Plaintiffs by Sandoz Inc., Lek Pharmaceuticals D.D.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 844 ANSWER to Amended Complaint, re: #802 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc..(Farnan, Kelly) |
Filing 843 [SEALED] ANSWER to Amended Complaint, re: #808 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Zhejiang Huahai Pharmaceutical Co. Ltd, Prinston Pharmaceutical Inc..(Fineman, Steven) |
Filing 842 [SEALED] ANSWER to Amended Complaint, re: #804 Amended Complaint, the third amended complaint, COUNTERCLAIM against All Plaintiffs by Apotex Corp., Apotex Inc..(Dorsney, Kenneth) |
Filing 841 [SEALED] ANSWER to Amended Complaint, re: #805 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
SO ORDERED, re #819 Stipulation, filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #818 STIPULATION TO EXTEND TIME for Plaintiffs and Defendants Sandoz Inc. and Lek Pharmaceuticals d.d. to Submit Their Joint Status Report to July 8, 2020 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #840 STIPULATION TO EXTEND TIME for Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. to answer, move or otherwise respond to Plaintiffs' Third Amended Complaint for Patent Infringement against Zydus Pharmaceuticals (USA) Inc. and filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd., #817 STIPULATION TO EXTEND TIME for the parties to submit their joint letter regarding expert discovery to July 1, 2020 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #821 STIPULATION TO EXTEND TIME by which Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc. shall respond to Plaintiffs' Second Amended Complaint for Patent Infringement (D.I. 811) to July 17, 2020 filed by Torrent Pharmaceuticals Limited, Torrent Pharma Inc. Signed by Judge Leonard P. Stark on 7/10/20. (ntl) |
Filing 840 STIPULATION TO EXTEND TIME for Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. to answer, move or otherwise respond to Plaintiffs' Third Amended Complaint for Patent Infringement against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (D.I. 812) to July 17, 2020 - filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
SO ORDERED, re #838 STIPULATION TO EXTEND TIME for Alkem to Respond to 3rd Amended Complaint to July 17, 2020 filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 7/9/20. (ntl) |
Filing 839 [SEALED] Joint STATUS REPORT (Plaintiffs' and Sandoz Defendants') by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 838 STIPULATION TO EXTEND TIME for Alkem to Respond to 3rd Amended Complaint to July 17, 2020 - filed by Alkem Laboratories Ltd.. (Kraman, Pilar) |
Filing 837 REDACTED VERSION of #804 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits A-F)(Dellinger, Megan) |
Filing 836 REDACTED VERSION of #819 Stipulation, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 835 REDACTED VERSION of #831 Answer to Amended Complaint, Counterclaim by Sigmapharm Laboratories LLC. (Phillips, John) |
Filing 834 STIPULATION TO EXTEND TIME For MSN Defendants to Answer Second Amended Complaint to July 17, 2020 - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Grivner, Geoffrey) |
SO ORDERED, re #834 STIPULATION TO EXTEND TIME For MSN Defendants to Answer Second Amended Complaint to July 17, 2020 filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 7/7/20. (ntl) |
Filing 833 REDACTED VERSION of #811 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan) |
Filing 832 REDACTED VERSION of #812 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-I)(Dellinger, Megan) |
Filing 831 [SEALED] ANSWER to Amended Complaint, re: #810 Amended Complaint, Affirmative Defenses, and, COUNTERCLAIM against All Plaintiffs by Sigmapharm Laboratories LLC.(Phillips, John) |
Filing 830 REDACTED VERSION of #806 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 829 ORAL ORDER: IT IS HEREBY ORDERED that, for reasons discussed during the recent teleconference (see D.I. 815), and having reviewed the parties' joint letter (D.I. 820), the bench trial in this matter is RESCHEDULED and will be held on some or all of the following dates, subject to the parties' time limits: January 4-8 and January 26-29, 2021. The pretrial conference will be held on December 22, 2020 at 4:00 p.m. and the proposed pretrial order is due on December 15. As the parties have agreed, the expert discovery deadline is now September 25, 2020. IT IS FURTHER ORDERED that: (i) Dr. Myerson's deposition on common issues of infringement and invalidity will not last more than 7 hours; (ii) each defendant contesting infringement (nine defendants) shall have a maximum of 4 additional hours to depose Dr. Myerson and either Dr. Morin (five defendants) or Dr. Gozzo (three defendants), as applicable, on infringement issues specific and unique to that defendant, provided that each such defendant shall notify Plaintiffs in advance of the beginning of expert depositions how many hours each defendant seeks to use with which of Drs. Myerson, Morin, and Gozzo; (iii) Dr. MacMillan's deposition will be limited to 9 hours; (iv) Dr. Lepore's deposition will be limited to 9 hours; (v) Dr. Rothschild's deposition will be limited to 14 hours; and (vi) all other depositions will be limited to 7 hours. The Court believes these limits reflect a reasonable and appropriate exercise of the Court's discretion, considering all circumstances, including the fact that this consolidated case is, in reality, multiple cases, and that each defendant asserting non-infringement must be given a full and fair opportunity to conduct expert discovery in preparation for trial. Plaintiffs' complaint that the aspects of Defendants' proposal the Court has adopted "would allow Defendants much more time with Plaintiffs' experts" is unpersuasive under the circumstances. Finally, IT IS ALSO ORDERED that: (i) Defendants' request for leave to serve a responsive expert report to Dr. Peck is GRANTED; (ii) Defendants shall file their responsive expert report two weeks from the date Plaintiffs approve their expert; and (iii) Plaintiffs may file a reply report no later than two weeks before Dr. Peck's deposition. Allowing Defendants to file a responsive report is justified and harmless because the Court only recently denied Defendants' motion to strike Dr. Peck's report, there is sufficient time in the schedule to allow all parties to take reasonable and necessary discovery on the issues addressed by Dr. Peck (and there is good cause for the further scheduling order modification requested by Defendants), and the Court will find having a full record on these issues useful to it as factfinder. ORDERED by Judge Leonard P. Stark on 7/6/20. (ntl) |
Filing 828 REDACTED VERSION of #810 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-H)(Dellinger, Megan) |
Filing 827 REDACTED VERSION of #809 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 826 REDACTED VERSION of #808 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 825 REDACTED VERSION of #807 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan) |
Filing 824 REDACTED VERSION of #805 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-D)(Dellinger, Megan) |
Filing 823 REDACTED VERSION of #803 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 822 REDACTED VERSION of #802 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 821 STIPULATION TO EXTEND TIME by which Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc. shall respond to Plaintiffs' Second Amended Complaint for Patent Infringement (D.I. 811) to July 17, 2020 - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Riley, Stephanie) |
Filing 820 Joint Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Expert Discovery. (Dellinger, Megan) |
Filing 819 [SEALED] Joint STIPULATION and [Proposed] Order Concerning Certain Documents and Facts by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 818 STIPULATION TO EXTEND TIME for Plaintiffs and Defendants Sandoz Inc. and Lek Pharmaceuticals d.d. to Submit Their Joint Status Report to July 8, 2020 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 817 STIPULATION TO EXTEND TIME for the parties to submit their joint letter regarding expert discovery to July 1, 2020 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 816 REPLY to Response to Motion re #794 MOTION to Dismiss Based upon Defendant Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd's Counterclaims Pertaining to U.S. Patent Nos. 9,125,908 and 9,125,909 filed by Prinston Pharmaceutical Inc.. (Fineman, Steven) |
Filing 815 Official Transcript of Telephone Conference on June 26, 2020 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, e-mail: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 7/20/2020. Redacted Transcript Deadline set for 7/30/2020. Release of Transcript Restriction set for 9/28/2020. (bpg) |
Document Unsealed -- #813 Memorandum Order. (ntl) |
Filing 814 ORDER re #813 Memorandum Order -- #415 MOTION to Dismiss and for partial Judgment on the Pleadings filed by Lek Pharmaceuticals D.D., Sandoz Inc. Signed by Judge Leonard P. Stark on 6/26/20. (ntl) |
Filing 813 MEMORANDUM ORDER re #415 MOTION to Dismiss and for for Partial Judgment on the Pleadings filed by Lek Pharmaceuticals D.D., Sandoz Inc. Signed by Judge Leonard P. Stark on 6/26/20. This order has been emailed to local counsel. (ntl) (Main Document 813 replaced on 6/26/2020) (ntl). (Main Document 813 UNSEALED and replaced on 6/29/2020) (ntl). Modified on 6/29/2020 (ntl). |
Filing 812 [SEALED] Third AMENDED COMPLAINT against Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-I)(Dellinger, Megan) |
Filing 811 [SEALED] Second AMENDED COMPLAINT against Torrent Pharma Inc., Torrent Pharmaceuticals Limited- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan) |
Filing 810 [SEALED] Second AMENDED COMPLAINT against Sigmapharm Laboratories LLC- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-H)(Dellinger, Megan) |
Filing 809 [SEALED] Third AMENDED COMPLAINT against Lek Pharmaceuticals D.D., Sandoz Inc.- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 808 [SEALED] Third AMENDED COMPLAINT against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 807 [SEALED] Second AMENDED COMPLAINT against MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan) |
Filing 806 [SEALED] Third AMENDED COMPLAINT against Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 805 [SEALED] Second AMENDED COMPLAINT against Lupin Limited, Lupin Pharmaceuticals Inc.- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-D)(Dellinger, Megan) |
Filing 804 [SEALED] Third AMENDED COMPLAINT against Apotex Corp., Apotex Inc., Apotex Research Private Limited- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 803 [SEALED] Third AMENDED COMPLAINT against Alkem Laboratories Ltd.- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 802 [SEALED] Third AMENDED COMPLAINT against Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 6/26/2020. (Court Reporter B. Gaffigan.) (ntl) |
Filing 801 ORAL ORDER: Having reviewed the parties' various filings relating to pending motions, IT IS HEREBY ORDERED that: (i) Plaintiffs' motion for leave to file amended complaints to add induced infringement of the '096 patent (D.I. 727) is GRANTED - Plaintiffs have demonstrated good cause and exercised diligence, given the timing with respect to which certain FDA label-related decisions were made and provided to Plaintiffs by certain Defendants; the allegations of induced infringement are not futile and will not cause undue prejudice to Defendants; also, judicial economy favors granting leave to resolve all disputes in a single trial; (ii) Lupin's and Macleods' motions to strike portions of Plaintiffs' expert reports served on April 16, 2020 (D.I. 747, 749) are GRANTED - Plaintiffs' parroting of Markush group claim language did not, in the context of the entirety of Plaintiffs' disclosures throughout this case (including especially the final infringement contentions), give these Defendants fair and timely notice that they were accused of infringement due to the presence of potentially every component of that group, and Plaintiffs have no persuasive explanation for taking until a month after final contentions were due (and many months after sample products were provided to and then tested by Plaintiffs) before adding the challenged contention in an expert report; allowing this new contention now would unduly prejudice Lupin and Macleods (who could have approached their infringement and/or invalidity cases differently had Plaintiffs made the new form allegation during fact discovery); nor do the other Pennypack factors help Plaintiffs (who can still proceed on their other timely-asserted claims of infringement of the '630 patent, who appear to have acted in willful disregard of their final infringement contentions deadline, and who have prejudiced and surprised these Defendants in a way that cannot easily be cured without disrupting the trial schedule); and (iii) Defendants' motion to strike the expert report of Dr. Carl Peck (D.I. 767) is DENIED, as the Court expects it will find his testimony (which the Court is not persuaded will be cumulative, improper legal opinion, or improper testimony about FDA intent or state of mind) helpful to it in its role as factfinder. IT IS FURTHER ORDERED that the teleconference tomorrow will not address the now-resolved motions but will instead be devoted to beginning a conversation about the timing and logistics of the remaining expert discovery and trial, all of which have been complicated by the ongoing effects of the coronavirus pandemic. (See generally D.I. 800) In preparation for that discussion, the parties are advised of the following: (i) due to the pandemic, the Court has had to reschedule five jury trials (including a high-priority detained defendant criminal trial) into the same slot in which the bench trial in this case is currently scheduled (October 13-23); (ii) the next open calendar slot during which the Court could give this case five or more largely consecutive, largely uninterrupted trial days is not until 2021; and (iii) the Court will be considering the possibility of conducting this trial remotely (where only court personnel - and no attorneys or witnesses - are in the courtroom) or partially-remotely (where a small number of lawyers and some of the witnesses are in the courtroom but most participants appear remotely) and to conducting it "after-hours" and on non-consecutive days, in an effort to hold the trial in a safe manner sometime during 2020. ORDERED by Judge Leonard P. Stark on 6/25/20. (ntl) |
Filing 800 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Scheduling and Logistical Issues Related to Expert Depositions and Trial. (Dellinger, Megan) |
Filing 799 RESPONSE to Motion re #794 MOTION to Dismiss Based upon Defendant Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd's Counterclaims Pertaining to U.S. Patent Nos. 9,125,908 and 9,125,909 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits A-B)(Dellinger, Megan) |
Filing 798 ORAL ORDER: IT IS HEREBY ORDERED that the Telephone Conference on June 26, 2020 will begin at 2:30 PM. ORDERED by Judge Leonard P. Stark on 6/23/20. (ntl) |
Filing 797 SO ORDERED, re #796 Consent Judgment -- Party Unichem Laboratories, Limited, Unichem Laboratories, Limited and Unichem Laboratories, Limited terminated. Attorney Michael J. Fink; Megan C. Haney; P. Branko Pejic; John C. Phillips, Jr; David A. Bilson and Paul A. Braier terminated. Signed by Judge Leonard P. Stark on 6/18/20. (ntl) |
Filing 796 PROPOSED CONSENT JUDGMENT between Plaintiffs and Unichem Laboratories, Limited by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 795 DECLARATION re #794 MOTION to Dismiss Based upon Defendant Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd's Counterclaims Pertaining to U.S. Patent Nos. 9,125,908 and 9,125,909 [Brent Batzer] by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Attachments: #1 Exhibit 1)(Fineman, Steven) |
Filing 794 MOTION to Dismiss Based upon Defendant Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd's Counterclaims Pertaining to U.S. Patent Nos. 9,125,908 and 9,125,909 - filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Attachments: #1 Text of Proposed Order)(Fineman, Steven) |
Filing 793 NOTICE OF SERVICE of Rebuttal Expert Report of Dr. Bart Kahr, Ph.D. filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 792 NOTICE OF SERVICE of Rebuttal Expert Report of Raj Suryanarayanan, Ph.D. filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 791 NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Rebuttal Noninfringement Expert Report of Jennifer Swift, Ph.D. filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie) |
Filing 790 NOTICE OF SERVICE of Rebuttal Expert Report of Dr. William E. Mayo Regarding NonInfringement of U.S. Patent Nos. 8,722,684, 8,969,355, 9,227,946, 9,861,630 and 9,278,096 filed by Alkem Laboratories Ltd..(Kraman, Pilar) |
Filing 789 NOTICE OF SERVICE of Responsive Expert Report of Anthony J. Rothschild and, M.D. and Rebuttal Expert Report of Victor I. Reus, M.D. filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 788 NOTICE OF SERVICE of Rebuttal Expert Report of Salvatore Lepore, Ph.D. filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 787 NOTICE OF SERVICE of the Rebuttal Expert Report of Michael Zaworotko, Ph.D. and the Rebuttal Expert Report of Dr. Mark D. Hollingsworth, Ph.D. on Behalf of Sigmapharm Laboratories, LLC filed by Sigmapharm Laboratories LLC.(Haney, Megan) |
Filing 786 NOTICE OF SERVICE of Rebuttal Expert Report of Mark J. Sacchetti, Ph.D. Regarding Noninfringement filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 785 NOTICE OF SERVICE of Expert Opinion filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey) |
Filing 784 NOTICE OF SERVICE of Rebuttal Expert Reports (served on various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 783 REDACTED VERSION of #777 Letter, Reply Letter Regarding their Motion to Strike the Expert Report of Dr. Carl Peck, M.D by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 782 NOTICE OF SERVICE of Rebuttal Expert Report filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey) |
Filing 781 NOTICE OF SERVICE of Expert Report of Jonathan W. Steed Ph.D. in Rebuttal to the Opening Expert Report of Myerson filed by Lek Pharmaceuticals D.D., Sandoz Inc..(Gattuso, Dominick) |
Filing 780 ORAL ORDER: IT IS HEREBY ORDERED that argument on #767 MOTION to Strike will also be heard during the June 26 teleconference. ORDERED by Judge Leonard P. Stark on 6/5/20. (ntl) |
SO ORDERED, re #776 STIPULATION for Leave to File a Motion to Dismiss Certain of Their Counterclaims filed by Zhejiang Huahai Pharmaceutical Co. Ltd, Prinston Pharmaceutical Inc. Signed by Judge Leonard P. Stark on 6/4/20. (ntl) |
SO ORDERED, re #775 STIPULATION TO EXTEND TIME Rebuttal Expert Reports and Reply Expert Reports to June 5, 2020 and July 24, 2020 respectively filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Unichem Laboratories, Limited, Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 6/4/20. (ntl) |
Filing 779 REDACTED VERSION of #774 Letter, by Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 778 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding a Request for Teleconference on Motion to Strike - re #767 MOTION to Strike The Expert Report of Carl C. Peck, #774 Letter, #777 Letter, #768 Letter,. (Gattuso, Dominick) |
Filing 777 [SEALED] Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Defendants' Reply Letter regarding their Motion to Strike the Expert Report of Dr. Carl Peck, M.D.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 776 STIPULATION for Leave to File a Motion to Dismiss Certain of Their Counterclaims by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Mowery, Katharine) |
Pro Hac Vice Attorney Karen L. Beckman for Macleods Pharma USA, Inc.,Karen L. Beckman for Macleods Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
Filing 775 STIPULATION TO EXTEND TIME Rebuttal Expert Reports and Reply Expert Reports to June 5, 2020 and July 24, 2020 respectively - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Phillips, John) |
Filing 774 [SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Defendants' Motion to Strike - re #767 MOTION to Strike The Expert Report of Carl C. Peck, #768 Letter,. (Attachments: #1 Exhibits 1-3)(Dellinger, Megan) |
Filing 773 REDACTED VERSION of #768 Letter, Defendants' Opening Letter Regarding their Motion to Strike The Expert Report of Dr. Carl Peck, M.D. by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Exhibits A-D [Shall Remain Under Seal], #2 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 772 ORAL ORDER: IT IS HEREBY ORDERED that the Court will hear argument by teleconference on the motions to amend and to strike (D.I. 727, 747, 749) on June 26, 2020 beginning at 1:30 p.m. Any party wishing to refer to slides or other materials shall provide a copy to the Court no later than 4:00 p.m. the day before the hearing. The parties can access the teleconference by dialing 877-336-1829 and using the access code 1408971. ORDERED by Judge Leonard P. Stark on 5/27/20. (ntl) |
Filing 771 REDACTED VERSION of #762 Letter, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Delcollo, Renee) |
Filing 770 REDACTED VERSION of #757 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-10)(Dellinger, Megan) |
Filing 769 SO ORDERED, re #761 Consent Judgment -- Party Hetero Labs Limited Unit-V, Hetero Labs Limited Unit-V, Hetero USA Inc., Hetero USA Inc., Hetero Labs Limited and Hetero Labs Limited terminated. Attorney John M. Seaman; A. Neal Seth; April M. Kirby and Alexander B. Owczarczak terminated. Signed by Judge Leonard P. Stark on 5/20/20. (ntl) |
Filing 768 [SEALED] Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Motion to Strike - re #767 MOTION to Strike The Expert Report of Carl C. Peck. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 767 MOTION to Strike The Expert Report of Carl C. Peck - filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certification Pursuant to 7.1.1, #2 Text of Proposed Order [Proposed] Order)(Gattuso, Dominick) |
Filing 766 REDACTED VERSION of #756 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 765 Letter to The Honorable Leonard P. Stark from James M. Lennon regarding requesting a teleconference on Defendants' Motion to Strike Portions of Plaintiffs' Expert Reports to Lupin - re #748 Letter, #756 Letter, #764 Letter, #747 MOTION to Strike portions of Plaintiffs' expert report. (Lennon, James) |
Filing 764 [SEALED] Letter to The Honorable Leonard P. Stark from James M. Lennon regarding Reply in Support of Defendants' Motion to Strike Portions of Plaintiffs' Expert Reports to Lupin - re #756 Letter, #750 Letter, #747 MOTION to Strike portions of Plaintiffs' expert report, #762 Letter,. (Attachments: #1 Exhibit 1, #2 Exhibit 2)(Lennon, James) |
Filing 763 Letter to The Honorable Chief Judge Leonard P. Stark from Renee Mosley Delcollo regarding the parties request a teleconference re Defendants' Motion to Strike Plaintiffs UntimelyInfringement Contentions D.I. 749 - re #750 Letter, #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions, #757 Letter, #762 Letter,. (Delcollo, Renee) |
Filing 762 [SEALED] SEALED Letter to The Honorable Chief Judge Leonard P. Stark from Renee Mosley Delcollo regarding Reply In Support of Its Motion to Strike Plaintiffs Untimely Infringement Contentions - re #750 Letter, #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions. (Delcollo, Renee) |
Filing 761 PROPOSED CONSENT JUDGMENT between Plaintiffs and Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 760 NOTICE to Take Deposition of Chintan Dholakia on May 20, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 759 SUBPOENA Returned Executed as to Dr. Roger McIntyre on May 5, 2020 (Phillips, John) |
Filing 758 SUBPOENA Returned Executed as to Anita Louise Hammer Clayton, M.D. on May 1, 2020 (Phillips, John) |
Filing 757 [SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Macleods' Motion to Strike Plaintiffs' Infringement Contentions. (Attachments: #1 Exhibit 1-10)(Dellinger, Megan) |
Filing 756 [SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Lupin's Motion to Strike Portions of Expert Reports. (Attachments: #1 Exhibit 1-3, #2 Exhibit 4-5, #3 Exhibit 6-8)(Dellinger, Megan) |
Filing 755 REDACTED VERSION of #748 Letter, by Lupin Limited, Lupin Pharmaceuticals Inc.. (Attachments: #1 Exhibit 1-5)(Lennon, James) |
Filing 754 REDACTED VERSION of #747 MOTION to Strike portions of Plaintiffs' expert report by Lupin Limited, Lupin Pharmaceuticals Inc.. (Attachments: #1 Exhibit A-C)(Lennon, James) |
Filing 753 REDACTED VERSION of #750 Letter, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Exhibit 1-4)(Delcollo, Renee) |
Filing 752 REDACTED VERSION of #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Text of Proposed Order)(Delcollo, Renee) |
Filing 751 STATEMENT re #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Delcollo, Renee) |
Filing 750 [SEALED] Letter to Honorable Chief Judge Leonard P. Stark from Renee Mosley Delcollo regarding Motion to Strike - re #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions. (Attachments: #1 Exhibit 1 - 4)(Delcollo, Renee) |
Filing 749 [SEALED] MOTION to Strike Plaintiffs' Untimely Infringement Contentions - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Text of Proposed Order)(Delcollo, Renee) |
CORRECTING ENTRY: Motion and letter docketed at D.I. 749-750 were removed from the docket as duplicative of D.I. 747-748. Exhibits A-C were added to D.I. 747 and Exhibits 1-5 were added to D.I. 748. D.I. 747-748 were placed under seal per the request of counsel. (ntl) |
Filing 748 [SEALED] Letter to Honorable Leonard P. Stark from James M. Lennon regarding Letter Brief regarding Defendants' Motion to Strike - re #747 MOTION to Strike portions of Plaintiffs' expert report. (Lennon, James) Modified on 5/7/2020 (ntl). (Additional attachment(s) added on 5/7/2020: #1 Exhibit 1, #2 Exhibit 2, #3 Exhibit 3, #4 Exhibit 4, #5 Exhibit 5) (ntl). |
Filing 747 [SEALED] MOTION to Strike portions of Plaintiffs' expert report - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) (Additional attachment(s) added on 5/7/2020: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C) (ntl). Modified on 5/7/2020 (ntl). |
Filing 746 REDACTED VERSION of #739 Letter, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
SO ORDERED, re #745 MOTION for Pro Hac Vice Appearance of Attorney Tedd W. Van Buskirk and Aaron S. Eckenthal filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 4/29/20. (ntl) |
Pro Hac Vice Attorney Aaron S. Eckenthal for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam) |
Pro Hac Vice Attorney Tedd W. Van Buskirk for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam) |
Filing 745 MOTION for Pro Hac Vice Appearance of Attorney Tedd W. Van Buskirk and Aaron S. Eckenthal - filed by Alkem Laboratories Ltd.. (Kraman, Pilar) |
Filing 744 REDACTED VERSION of #737 Letter, by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibits 1-12, #2 Exhibit 13, #3 Exhibits 14-15, #4 Exhibit 16)(Phillips, John) |
Filing 743 NOTICE requesting Clerk to remove Allison Schmitt as co-counsel. Reason for request: no longer with firm. (Dellinger, Megan) |
Filing 742 REDACTED VERSION of #728 Letter, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C, #2 Exhibit D-H)(Dellinger, Megan) |
Filing 741 REDACTED VERSION of #727 MOTION for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1a-7b, #2 Exhibit 8a-14b)(Dellinger, Megan) |
Filing 740 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Request for Teleconference to Address Plaintiffs' Motion for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent - re #727 MOTION for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent. (Dellinger, Megan) |
Filing 739 [SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Reply in Support of Motion for Leave to File Amended Complaints Asserting Induced Infringement of the '096 Patent - re #727 MOTION for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent. (Dellinger, Megan) |
Filing 738 Amended Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Limited, Corporate Parent Lupin Inc., Corporate Parent Nanomi B.V. for Lupin Pharmaceuticals Inc. filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) |
SO ORDERED, re #731 STIPULATION TO EXTEND TIME for Defendants to file their responsive letter in opposition to Plaintiffs' Motion seeking leave to amend to April 20, 2020 filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Unichem Laboratories, Limited, Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 4/22/20. (ntl) |
SO ORDERED, re #730 Consent Judgment -- Party Cipla USA Inc., Cipla USA Inc., Cipla Limited and Cipla Limited terminated. Attorney Karen L. Pascale; Tedd W. Van Buskirk; Robert M. Vrana; Aaron S. Eckenthal and William L. Mentlik terminated. Signed by Judge Leonard P. Stark on 4/22/20. (ntl) |
Filing 737 [SEALED] Letter to the Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Opposition to Plaintiffs' Motion Seeking Leave to Amend Complaints - re #728 Letter,. (Attachments: #1 Exhibit 1-16)(Phillips, John) |
Filing 736 NOTICE OF SERVICE of Opening Expert Report of Anthony J. Rothschild, M.D. and Opening Expert Report of Victor I. Reus, M.D. filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 735 NOTICE OF SERVICE of Opening Expert Report of Dr. Salvatore Lepore filed by Sigmapharm Laboratories LLC.(Haney, Megan) |
Pro Hac Vice Attorney Brent A. Batzer for Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
Filing 734 NOTICE OF SERVICE of Opening Expert Reports (served on various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 733 MOTION for Pro Hac Vice Appearance of Attorney Grant S. Shackelford - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Attachments: #1 Text of Proposed Order, #2 Certification of Grant S. Shackelford)(Grivner, Geoffrey) |
SO ORDERED, re #733 MOTION for Pro Hac Vice Appearance of Attorney Grant S. Shackelford filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 4/17/20. (ntl) |
Filing 732 NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.s Opening Expert Report of Jonathan W. Steed, Ph.D. Pursuant to Federal Rule of Civil Procedure 26(A)(2)(B) filed by Lek Pharmaceuticals D.D., Sandoz Inc..(Gattuso, Dominick) |
Filing 731 STIPULATION TO EXTEND TIME for Defendants to file their responsive letter in opposition to Plaintiffs' Motion seeking leave to amend to April 20, 2020 - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
SO ORDERED, re #726 STIPULATION for Limited Waiver of Protective Order filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Unichem Laboratories, Limited, Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 4/13/20. (ntl) |
Filing 730 PROPOSED CONSENT JUDGMENT between Plaintiffs and Cipla Limited and Cipla USA Inc. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
SO ORDERED, re #721 STIPULATION TO EXTEND TIME Various Deadlines to Various Dates filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Unichem Laboratories, Limited, Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 4/7/20. (ntl) |
Filing 729 NOTICE OF SERVICE of Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories to Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V (Nos. 1, 2, 7, & 8) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John) |
Filing 728 [SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Plaintiffs' Motion for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent - re #727 MOTION for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent. (Attachments: #1 Exhibit A-C, #2 Exhibit D-H)(Dellinger, Megan) |
Filing 727 [SEALED] MOTION for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1a-7b, #2 Exhibit 8a-14b)(Dellinger, Megan) |
SO ORDERED, re #725 MOTION for Pro Hac Vice Appearance of Attorney Brian H. Gold and S. Lloyd Smith filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 4/7/20. (ntl) |
Filing 726 STIPULATION for Limited Waiver of Protective Order by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 725 MOTION for Pro Hac Vice Appearance of Attorney Brian H. Gold and S. Lloyd Smith - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Attachments: #1 Text of Proposed Order, #2 Certification of Brian H. Gold, #3 Certification of S. Lloyd Smith)(Grivner, Geoffrey) |
Filing 724 NOTICE OF SERVICE of (1) Defendants Macleods Pharmaceuticals, Ltd.s and Macleods Pharma USA, Inc.s First Supplemental Responses to Plaintiffs First Set of Interrogatories to Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Nos. 115) and (2) Defendants Macleods Pharmaceuticals, Ltd.s and Macleods Pharma USA, Inc.s Supplemental Answers to Plaintiffs Third Set of Interrogatories (Nos. 17-23) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 723 NOTICE requesting Clerk to remove Philip Hirshchorn, Kimberly Coghill, and Erin Dunston as co-counsel.. (Grivner, Geoffrey) |
Pro Hac Vice Attorney Jason W. Schigelone for Lek Pharmaceuticals D.D. and Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
Filing 722 MOTION for Pro Hac Vice Appearance of Attorney Jason W. Schigelone - filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Gattuso, Dominick) |
SO ORDERED, re #722 MOTION for Pro Hac Vice Appearance of Attorney Jason W. Schigelone filed by Lek Pharmaceuticals D.D., Sandoz Inc. Signed by Judge Leonard P. Stark on 4/2/20. (ntl) |
Filing 721 STIPULATION TO EXTEND TIME Various Deadlines to Various Dates - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
Filing 720 NOTICE OF SERVICE of Defendants' Joint Second Supplemental Invalidity Contentions filed by Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 719 NOTICE OF SERVICE of Defendants Cipla Limited and Cipla USA Inc.'s Supplemental Response to Interrogatories (Nos. 22-25) filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen) |
Filing 718 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Supplemental Objections and Responses to Plaintiffs' Interrogatory No. 9 filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 717 NOTICE OF SERVICE of Sigmapharm Laboratories, LLC's Supplemental Objections and Answers to Plaintiffs' First Set of Interrogatories to Sigmapharm Laboratories, LLC (Nos. 5, 9-11, & 14) filed by Sigmapharm Laboratories LLC.(Haney, Megan) |
Filing 716 MEMORANDUM ORDER: Having reviewed the parties' motion and letters regarding Defendants' use of Dr. Rothschild as an expert (D.I. #698 , #704 , #711 ), and having heard argument on March 13, 2020, IT IS HEREBY ORDERED that Plaintiffs' requests to disqualify Dr. Rothschild as an expert and to prevent him from receiving access to materials designated as Confidential Information under the Protective Order are DENIED. Signed by Judge Jennifer L. Hall on 3/18/2020. (ceg) |
Filing 715 REDACTED VERSION of #711 Letter, by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A-F [Shall Remain Under Seal], #2 Exhibit Certificate of Service)(Gattuso, Dominick) |
CORRECTING ENTRY: Corrected letter added to D.I. 714 per request of counsel. (ntl) |
Filing 714 REDACTED VERSION of #704 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-10)(Dellinger, Megan) (Main Document 714 replaced on 3/17/2020) (ntl). |
SO ORDERED, re #712 MOTION for Pro Hac Vice Appearance of Attorney Jennifer D. Cieluch of Covington & Burling LLP filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 3/16/20. (ntl) |
Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute held on 3/13/2020.(*Court Reporter Adam Miller) (nmg) |
Filing 713 NOTICE OF SERVICE of Plaintiffs' Final Infringement Contentions Against Sigmapharm Laboratories, LLC filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 712 MOTION for Pro Hac Vice Appearance of Attorney Jennifer D. Cieluch of Covington & Burling LLP - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 711 [SEALED] Letter to The Honorable Jennifer L. Hall from Dominick T. Gattuso, Esquire regarding Defendants Response to Plaintiffs' Letter Brief - re #704 Letter. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 710 REDACTED VERSION of #697 Letter by Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit 1)(Phillips, John) |
SO ORDERED, re #700 MOTION for Pro Hac Vice Appearance of Attorney Dustin L. Taylor filed by Sigmapharm Laboratories LLC. Signed by Judge Leonard P. Stark on 3/11/20. (ntl) |
Pro Hac Vice Attorney Dustin L. Taylor for Sigmapharm Laboratories LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d), Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam) |
Filing 709 ORAL ORDER: Having considered Plaintiffs' motion regarding discovery disputes (D.I. 688), and the associated letter briefing (D.I. 692, 697), and having heard argument on March 9, 2020, IT IS HEREBY ORDERED that Plaintiffs' motion is GRANTED-IN-PART and DENIED-IN-PART. (1) Regarding the Rule 30(b)(6) designee in dispute, Zydus shall make the designee available for seven hours of deposition by video conference, which may occur over two days. Zydus shall pay the expenses associated with conducting the video conference. (2) Regarding Plaintiffs' requests for Rule 30(b)(6) deposition testimony, for topic numbers 4, 8, 11, 29, and 31-33, the Court will DENY Plaintiffs' request for a designee to testify about all testing. The record reflects that Zydus has produced all testing data, and Zydus has designated a witness to testify about the types of testing relevant to the asserted claims. For topic numbers 57-60, the Court will DENY Plaintiffs' requests for the reasons argued by Zydus. For topic numbers 34, 35, 37, and 44 the Court will GRANT Plaintiffs' requests because those topics are potentially relevant to validity (particularly objective indicia of non-obviousness) or infringement. Plaintiffs' requests regarding topic numbers 24, 25, and 47 were resolved pursuant to agreement of the parties during the teleconference. (3) Regarding Plaintiffs' requests for supplemental responses to interrogatories 1, 2, 4, 6, 7, 10, 13-18, 21-25, the Court will DENY the requests. In light of the breadth of Plaintiff's requests, the document discovery already provided by Zydus, the Court's decision above regarding Rule 30(b)(6) witness testimony, and the Rule 30(b)(6) testimony already provided by Zydus, the record does not reflect that the additional information sought is proportional to the needs of the case. The Court will GRANT Plaintiffs' request as to interrogatory 9. IT IS FURTHER ORDERED that, not later than March 20, 2020, Zydus shall submit its supplemental response to interrogatory 9 and shall designate a Rule 30(b)(6) witness for the topics authorized above. ORDERED by Judge Jennifer L. Hall on 3/10/20. (JLH) |
Filing 708 ORAL ORDER:Having considered Plaintiffs' motion regarding discovery disputes (D.I. 686), and the associated letter briefing (D.I. 691, 696), and having heard argument on March 9, 2020, IT IS HEREBY ORDERED that Plaintiffs' motion is GRANTED-IN-PART and DENIED-IN-PART. Regarding interrogatories 9, 10, and 14, the Court disagrees with Sigmapharm's assertion that the information sought is irrelevant. Sigmapharm shall provide responses to interrogatories 5, 9, 10, 11, and 14, as those interrogatories are potentially relevant to validity of the patents-in-suit (particularly to objective indicia of non-obviousness) or infringement, proportional to the needs of the case, and the current record before the Court does not reflect that they are cumulative to other discovery provided by Sigmapharm. For the remainder of the interrogatories identified by Plaintiffs (2, 6, 7, 12, 15 and 16), in light of the breadth of Plaintiffs' requests, and in view of the document discovery already provided by Sigmapharm, the record does not demonstrate that the additional information sought is proportional to the needs of the case. IT IS FURTHER ORDERED that, not later than March 20, 2020, Sigmapharm shall submit supplemental responses to interrogatories 5, 9, 10, 11, and 14. ORDERED by Judge Jennifer L. Hall on 3/10/20. (JLH) |
Filing 707 REDACTED VERSION of #694 Stipulation, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 706 REDACTED VERSION of #692 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits 1-11)(Dellinger, Megan) |
SO ORDERED, re #694 Stipulation and Order Regarding Infringement filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 3/10/20. (ntl) |
Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute held on 3/9/2020.(*Court Reporter Lorraine Marino) (nmg) |
Filing 705 NOTICE OF SERVICE of Plaintiffs' Final Infringement Contentions Against Defendants (directed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 704 [SEALED] Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Protective Order Disputes Related to Defendants Expert Dr. Anthony J. Rothschild. (Attachments: #1 Exhibit 1-10)(Dellinger, Megan) |
Filing 703 NOTICE OF SERVICE of Supplemental Objections and Responses to Plaintiffs' Third Set of Interrogatories filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey) |
Filing 702 NOTICE OF SERVICE of Defendants' Joint Supplemental Invalidity Contentions filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 701 NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Supplemental Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos. 17, 22, 23) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie) |
Filing 700 MOTION for Pro Hac Vice Appearance of Attorney Dustin L. Taylor - filed by Sigmapharm Laboratories LLC. (Attachments: #1 Taylor Pro Hac Certification)(Haney, Megan) |
Filing 699 REDACTED VERSION of #691 Letter, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits 1-12)(Dellinger, Megan) |
ORAL ORDER Setting Teleconference: The Court has reviewed the Joint Motion for Teleconference to Resolve Discovery Disputes (D.I. #698 ). A discovery dispute teleconference is scheduled for March 13, 2020 at 02:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than March 9, 2020, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than March 11, 2020, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Two courtesy copies of the letters are to be hand delivered to the Clerk's Office within one hour of e-filing. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Entered by Judge Jennifer L. Hall on 3/5/2020. (nmg) |
Filing 698 Joint MOTION for Teleconference to Resolve Protective Order Disputes - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 697 [SEALED] Letter to The Honorable Jennifer L. Hall from John C. Phillips, Jr. regarding Zydus' Response to Plaintiff's Opening Discovery Letter - re #692 Letter. (Attachments: #1 Exhibit 1)(Phillips, John) |
Filing 696 Letter to The Honorable Jennifer L. Hall from John C. Phillips, Jr. regarding in response to Plaintiffs' February 27, 2020 letter regarding Sigmapharm's responses to certain interrogatories - re #691 Letter,. (Phillips, John) |
Filing 695 REDACTED VERSION of #689 Stipulation, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 694 [SEALED] STIPULATION and [Proposed] Order Regarding Infringement by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 693 NOTICE OF SERVICE of Sigmapharm Laboratories, LLC's Supplemental Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos. 18-24) filed by Sigmapharm Laboratories LLC.(Phillips, John) |
Filing 692 [SEALED] Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Discovery Disputes with Zydus. (Attachments: #1 Exhibits 1-11)(Dellinger, Megan) |
SO ORDERED, re #689 [SEALED] STIPULATION and [Proposed] Order of Infringement by Torrent of Certain Asserted Claims. Signed by Judge Leonard P. Stark on 2/27/20. (ntl) |
Filing 691 [SEALED] Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Plaintiffs' Motion to Compel Sigmapharm Laboratories, LLC to Supplement Its Interrogatory Responses - re 687 Order Setting Teleconference,,,,. (Attachments: #1 Exhibit 1-12)(Dellinger, Megan) |
Filing 690 ORAL ORDER Setting Teleconference: The Court has reviewed the Joint Motion for Teleconference to Resolve Discovery Disputes (D.I. #688 ). A discovery dispute teleconference is scheduled for March 9, 2020 at 03:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than February 28, 2020, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than March 4, 2020, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that partys reasons for its opposition. Two courtesy copies of the letters are to be hand delivered to the Clerk's Office within one hour of e-filing. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Signed by Judge Jennifer L. Hall on 2/26/2020. (ceg) |
Filing 689 [SEALED] STIPULATION and [Proposed] Order of Infringement by Torrent of Certain Asserted Claims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 688 Joint MOTION for Teleconference to Resolve Discovery Disputes - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 687 ORAL ORDER Setting Teleconference: The Court has reviewed Plaintiffs' Motion for Teleconference to Resolve Discovery Disputes (D.I. #686 ). A discovery dispute teleconference is scheduled for March 9, 2020 at 02:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than February 27, 2020, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than March 3, 2020, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Two courtesy copies of the letters are to be hand delivered to the Clerk's Office within one hour of e-filing. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Jennifer L. Hall on 2/24/2020. (ceg) |
Filing 686 MOTION for Teleconference to Resolve Discovery Disputes - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 685 REDACTED VERSION of #680 Stipulation by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 684 NOTICE of Withdrawal of Counsel by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited (Pedi, Nicole) |
SO ORDERED, re #680 Stipulation. Signed by Judge Leonard P. Stark on 2/20/20. (ntl) |
SO ORDERED, re #679 Joint STIPULATION and [Proposed] Order Concerning Authenticity of Evidence. Signed by Judge Leonard P. Stark on 2/19/20. (ntl) |
Filing 683 ORDER re #682 Memorandum Opinion regarding claim construction. Signed by Judge Leonard P. Stark on 2/18/20. (ntl) |
Filing 682 MEMORANDUM OPINION re claim construction. Signed by Judge Leonard P. Stark on 2/18/20. (ntl) |
Filing 681 ORAL ORDER: In light of the Stipulation filed on 2/14/2020 (D.I. 680), the ADR teleconference set for 2/18/2020 is cancelled. Ordered by Judge Christopher J. Burke on 2/18/2020. (dlb) |
Filing 680 [SEALED] STIPULATION by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 679 Joint STIPULATION and [Proposed] Order Concerning Authenticity of Evidence by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 678 NOTICE OF SERVICE of Defendants Cipla Limited and Cipla USA Inc.'s Supplemental Response to Interrogatories (Nos. 2, 13, 16 & 19) filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen) |
Filing 677 ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that counsel shall file a Motion for Teleconference to Resolve Discovery Dispute. The suggested text for this motion can be found in Judge Hall's portion of the Court"s website, in the "Forms" tab, under the heading "Motion for Teleconference to Resolve Discovery/Protective Order Disputes." The parties need not include information previously provided in their letter to Judge Stark. The dispute will thereafter be addressed in the manner set forth in the Scheduling Order. ORDERED by Judge Jennifer L. Hall on 2/6/2020. (ceg) |
Filing 676 NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Rule 31 Notice of Deposition by Written Questions to Plaintiffs filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 675 ORAL ORDER: IT IS HEREBY ORDERED that the pending discovery disputes (see D.I. 628, 660, 661) and all future discovery disputes in this matter are REFERRED to Judge Hall for resolution in whatever manner she deems fit. All future requests for resolution of discovery disputes should be addressed to Judge Hall and not to Judge Stark. ORDERED by Judge Leonard P. Stark on 2/5/2020. (ntl) |
Filing 674 NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Corrected Supplemental Objections and Responses to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie) |
Filing 673 NOTICE to Take Deposition of Siva Vaithiyalingam on February 18, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 672 NOTICE to Take Deposition of Manjinder Singh on February 21, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 671 NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Supplemental Objections and Responses to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie) |
SO ORDERED, re #670 MOTION for Pro Hac Vice Appearance of Attorney Charles A. Weiss filed by Apicore US LLC. Signed by Judge Leonard P. Stark on 1/30/20. (ntl) |
Filing 670 MOTION for Pro Hac Vice Appearance of Attorney Charles A. Weiss - filed by Apicore US LLC. (Dorsney, Kenneth) |
Filing 669 ORDER Setting Mediation Conferences: A Telephone Conference is set with Plaintiffs andDefendant Apicore US LLC. for 2/18/2020 at 10:00 AM before Judge Christopher J. Burke.Signed by Judge Christopher J. Burke on 1/28/2020. (dlb) |
Pro Hac Vice Attorney Yixin H. Tang for Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
Filing 668 NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s Supplemental Response to Plaintiffs' Interrogatory No. 5 filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 667 NOTICE OF SERVICE of Heteros Supplemental Objections and Responses to Plaintiffs First Set of Requests for Admission No. 29 filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John) |
Filing 666 NOTICE to Take Deposition of Virendra Srivastava on January 30, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
SO ORDERED, re #663 STIPULATION TO EXTEND TIME Regarding Certain Deadlines to Various Dates filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 1/27/20. (ntl) |
Filing 665 REDACTED VERSION of #658 Notice (Other) Defendants' Rule 31 Notice of Deposition by Written Questions to Plaintiffs by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick) |
Filing 664 NOTICE requesting Clerk to remove Richard J. Berman, Janine A. Carlan, Bradford C. Frese, Gary A. Coad and Fannyben D. Patel as co-counsel.. (Mowery, Katharine) |
SO ORDERED, re #662 MOTION for Pro Hac Vice Appearance of Attorney Shashank Upadhye, Yixin H. Tang and Brent Batzer filed by Zhejiang Huahai Pharmaceutical Co. Ltd, Prinston Pharmaceutical Inc. Signed by Judge Leonard P. Stark on 1/24/20. (ntl) |
Pro Hac Vice Attorney Shashank D. Upadhye for Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
Filing 663 STIPULATION TO EXTEND TIME Regarding Certain Deadlines to Various Dates - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 662 MOTION for Pro Hac Vice Appearance of Attorney Shashank Upadhye, Yixin H. Tang and Brent Batzer - filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Fineman, Steven) |
Filing 661 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Request for a Discovery Conference. (Dellinger, Megan) |
Filing 660 Letter to The Honorable Leonard P. Stark from Renee M. Mosley regarding Joint Request to Schedule Discovery Teleconference. (Mosley, Renee) |
Filing 659 JOINDER by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, joining in #658 Notice (Other) . (Grivner, Geoffrey) |
Filing 658 [SEALED] NOTICE of Defendants' Rule 31 Notice of Deposition by Written Questions to Plaintiffs by Lek Pharmaceuticals d.d., Sandoz Inc. with Exhibit A (Gattuso, Dominick) |
Filing 657 NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.'s First Amended Objections and Responses to Plaintiffs' Notice of Deposition under Fed. R. Civ. P. 30(b)(6) [Confidential] filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick) |
Filing 656 NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s Objections and Responses to Plaintiffs' Rule 30(b)(6) Notice of Deposition to Alembic filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
SO ORDERED, re #652 STIPULATION TO EXTEND TIME to serve final infringement and invalidity contentions to February 14, 2020 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 1/13/20. (ntl) |
Filing 655 NOTICE to Take Deposition of Elizabeth Purcell on January 16, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 654 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Sandoz Inc. and Lek Pharmaceuticals d.d.'s Letter of January 3, 2020 - re #648 Letter,. (Dellinger, Megan) |
Filing 653 MOTION for Pro Hac Vice Appearance of Attorney Sumner, Evan T. - filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Pedi, Nicole) |
SO ORDERED, re #653 MOTION for Pro Hac Vice Appearance of Attorney Evan T. Sumner filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. Signed by Judge Leonard P. Stark on 1/9/20. (ntl) |
Pro Hac Vice Attorney Evan T. Sumner for Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lak) |
Filing 652 STIPULATION TO EXTEND TIME to serve final infringement and invalidity contentions to February 14, 2020 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 651 NOTICE to Take Deposition of Chris Valosky on January 13, 2020 at 8:30 AM CT filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 650 NOTICE to Take Deposition of Chris Valosky on January 13, 2020 at 9:00 CT filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 649 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Defendants Sandoz Inc. and Lek Pharmaceuticals d.d's letter of January 3, 2020. (Dellinger, Megan) |
Filing 648 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Defendant Sandoz Inc. and Lek Pharmaceuticals' Motion to Dismiss [DI 415] - re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c). (Gattuso, Dominick) |
Filing 647 NOTICE to Take Deposition of Vishal Kulkarni on January 8, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 646 NOTICE to Take Deposition of Ujwal Chhabra on January 27, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 645 NOTICE to Take Deposition of Prashant Mandaogade on January 28, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 644 NOTICE to Take Deposition of Hitesh Kumar Maheshwari on January 15, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 643 NOTICE to Take Deposition of G. Kesavan on January 13, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 642 Official Transcript of Claim Construction Hearing held on December 18, 2019 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Email: Brian_Gaffigan@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/23/2020. Redacted Transcript Deadline set for 2/3/2020. Release of Transcript Restriction set for 4/1/2020.(bpg) |
SO ORDERED, re #634 Joint STIPULATION TO EXTEND TIME for taking previously noticed fact depositions to January 28, 2020 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 1/2/20. (ntl) |
SO ORDERED, re #626 STIPULATION TO EXTEND TIME for Defendant Unichem Laboratories, Limited to respond to Plaintiffs' First Set of Requests for Admission to December 24, 2019 filed by Unichem Laboratories, Limited, #632 STIPULATION TO EXTEND TIME Response to Requests for Admission to December 27, 2019 filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 12/30/19. (ntl) |
Filing 641 NOTICE OF SERVICE of 1) Defendants Cipla Limiteds and Cipla USA Inc.s [Supplemental] Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); 2) Defendants Cipla Limiteds and Cipla USA Inc.s Supplemental Response to Plaintiffs Interrogatory Nos. 1, 5-7, 9, 10, 12, 14, 15, 17, 18 [First Set] [CONFIDENTIAL]; 3) Defendants Cipla Limiteds and Cipla USA Inc.s Response to Plaintiffs Third Set of Interrogatories (Nos. 21-25) [CONFIDENTIAL]; and 4)Defendants Cipla Limiteds and Cipla USA Inc.s Response to Plaintiffs First Set of Requests for Admission (Nos. 1-57) [CONFIDENTIAL], filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen) |
Filing 640 NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s First Set of Interrogatories to Plaintiffs (Nos. 1-3) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 639 NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Alembic's First Set of Requests for the Production of Documents (Nos. 1-8) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 638 NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants Macleods Pharmaceuticals Limited and Macleods Pharma USA Inc.'s First Set of Requests for Admission to Plaintiffs (Nos. 1-20) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 637 NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Unichem Laboratories, Limited's First Set of Individual Interrogatories to Plaintiffs (No. 1), (2) Plaintiffs' Objections and Responses to Unichem Laboratories, Limited's First Set of Individual Requests for Production of Documents and Things to Plaintiffs (Nos. 1-4), and (3) Plaintiffs' Objections and Responses to Defendant Unichem Laboratories, Limited's First Set of Requests for Admission to Plaintiffs (Nos. 1-20) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 636 NOTICE OF SERVICE of Unichem Laboratories, Limited's Responses and Objections to Plaintiffs' First Set of Requests for Admission (Nos. 1-52) filed by Unichem Laboratories, Limited.(Haney, Megan) |
Filing 635 NOTICE OF SERVICE of (1) Defendants Macleods Pharmaceuticals, Ltd.s and Macleods Pharma USA, Inc.s Responses to Plaintiffs First Set of Requests for Admission and (2) Defendants Macleods Pharmaceuticals, Ltd.s and Macleods Pharma USA, Inc.s Answers to Plaintiffs Third Set of Interrogatories (Nos. 17-23) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Mosley, Renee) |
Filing 634 Joint STIPULATION TO EXTEND TIME for taking previously noticed fact depositions to January 28, 2020 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 633 REDACTED VERSION of #608 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 632 STIPULATION TO EXTEND TIME Response to Requests for Admission to December 27, 2019 - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Grivner, Geoffrey) |
Filing 631 NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s (1) Objections and Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-55), (2) Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos. 17-23) and (3) Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 2, 3, 4, 7, 8, 9,10, 13, 14 and 15) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie) |
Filing 630 NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s: 1) Responses to Plaintiffs' Requests for Admission (Nos. 1-53); and 2) Response to Plaintiffs' Third Set of Interrogatories (Nos. 17-23) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 629 NOTICE OF SERVICE of (i) Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Responses and Objections to Plaintiffs' Third Set of Interrogatories (Nos. 10-16) and (ii) Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Objections and Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-38) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John) |
Filing 628 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding request for the scheduling of a discovery conference. (Dellinger, Megan) |
Filing 627 NOTICE OF SERVICE of Plaintiffs' Supplemental Initial Disclosures Pursuant to Rule 26(a)(1) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 626 STIPULATION TO EXTEND TIME for Defendant Unichem Laboratories, Limited to respond to Plaintiffs' First Set of Requests for Admission to December 24, 2019 - filed by Unichem Laboratories, Limited. (Haney, Megan) |
Filing 625 NOTICE OF SERVICE of copies of (i) of Sandoz Inc. and Lek Pharmaceuticals d.d.s Objections and Responses to Plaintiffs Fourth Set of Interrogatories (Nos. 24-25) [CONFIDENTIAL]; and, (ii) Sandoz Inc. and Lek Pharmaceuticals d.d.s Objections and Responses to Plaintiffs Second Set of Requests for Admission (Nos. 12- 57) [ CONFIDENTIAL] was filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick) |
Filing 624 NOTICE OF SERVICE of Defendants Objections and Responses to Third Set of Interrogatories (Nos. 10-16) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine) |
Filing 623 NOTICE OF SERVICE of Defendants Objections and Responses to First Set of Requests For Admission (Nos. 1-39) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine) |
Filing 622 NOTICE OF SERVICE of (1) Sigmapharm Laboratories, LLC's Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos. 18-24); and (2) Defendant Sigmapharm Laboratories, LLC's Response to Plaintiffs' First Set of Requests for Admission to Sigmapharm Laboratories, LLC (Nos. 1-57) filed by Sigmapharm Laboratories LLC.(Haney, Megan) |
Filing 621 NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' First Set of Requests for Admissions (Nos. 1-57); and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos. 21-25) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 620 NOTICE OF SERVICE of Defendant Unichem's Responses and Objections to Plaintiffs' Third Set of Interrogatories to Unichem Laboratories, Limited (Nos. 16-22) filed by Unichem Laboratories, Limited.(Haney, Megan) |
Filing 619 NOTICE OF SERVICE of (1) Defendant Lupin Limited and Lupin Pharmaceuticals, Inc.'s Response to Plaintiffs' First Set of Requests for Admission; and (2) Lupin's Responses and Objections to Plaintiffs' Third Set of Interrogatories (Nos. 20-25) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
Filing 618 NOTICE OF SERVICE of (1) Apotex's responses to Plaintiffs' First Set of Requests for Admission; and (2) Apotex's responses to Plaintiffs' Third Set of Interrogatories (Nos. 16-22) filed by Apotex Corp., Apotex Inc., Apotex Research Private Limited.(Dorsney, Kenneth) |
Filing 617 NOTICE OF SERVICE of (1) Apicore's response to Plaintiffs' First Set of Requests for Admission; and (2) Apicore's response to Plaintiffs' Third Set of Interrogatories filed by Apicore US LLC.(Dorsney, Kenneth) |
Filing 616 NOTICE OF SERVICE of 1) Defendant Alkem Laboratories Ltd.s Responses to Requests for Admissions Nos. 1-57; and 2) Defendant Alkem Laboratories Ltd.s Response to Plaintiffs Third Set of Interrogatories (Nos. 17-23) filed by Alkem Laboratories Ltd..(Kraman, Pilar) |
Filing 615 NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendant Apotex's Interrogatories to Plaintiffs (Nos. 1-2) (2) Plaintiffs' Objections and Responses to Defendants Prinston Pharmaceutical Inc.'s and Zhejiang Huahai Pharmaceutical Co., Ltd.'s First Set of Individual Interrogatories to Plaintiffs (Nos. 1-5) (3) Plaintiffs' Objections and Responses to Defendant Alembic's First Set of Interrogatories to Plaintiffs (Nos. 1-5) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 614 REDACTED VERSION of #605 Letter, to the Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding regarding Sandoz Motion [DI 415] by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A, #2 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 613 ORAL ORDER Setting Mediation Conference: A Telephone Conference is set for 1/27/2020 at 10:30 AM before Judge Christopher J. Burke to discuss ADR. Counsel for Plaintiffs shall initiate the call. Ordered by Judge Christopher J. Burke on 12/19/2019. (dlb) |
SO ORDERED, re #612 MOTION for Pro Hac Vice Appearance of Attorney Taylor J. Kelson filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 12/19/19. (ntl) |
Minute Entry for proceedings held before Judge Leonard P. Stark - Markman/Oral Argument/Discovery Hearing held on 12/18/2019. (Court Reporter B. Gaffigan.) (ntl) |
Filing 612 MOTION for Pro Hac Vice Appearance of Attorney Taylor J. Kelson - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 611 NOTICE OF SERVICE of Defendants' Responses and Objections to Plaintiffs' Notice of Deposition to Defendants Cipla Limited and Cipla USA Inc.s Under Fed. R. Civ. P. 30(b)(6) [CONFIDENTIAL] filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen) |
SO ORDERED, re #610 MOTION for Pro Hac Vice Appearance of Attorney Kurt G. Calia filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 12/17/19. (ntl) |
Filing 610 MOTION for Pro Hac Vice Appearance of Attorney Kurt G. Calia - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 609 NOTICE requesting Clerk to remove Judy K. He as co-counsel. Reason for request: No longer associated with the case. (Gattuso, Dominick) |
Filing 608 [SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Defendants' December 11, 2019 Letter Regarding Discovery Dispute. (Dellinger, Megan) |
Filing 607 NOTICE OF SERVICE of Defendant Unichem's Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories to Unichem Laboratories, Limited (Nos. 1-14) filed by Unichem Laboratories, Limited.(Phillips, John) |
Filing 606 NOTICE OF SERVICE of 1) Defendant Alkem Laboratories Ltd.s Supplemental Responses to Interrogatories Nos. 1, 5-7, 9, 10, 12, 14, and 15; and 2) Defendant Alkem Laboratories Ltd.s Responses and Objections to Plaintiffs Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Alkem Laboratories Ltd..(Kraman, Pilar) |
Filing 605 [SEALED] Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Sandoz Motion to Dimiss (D.I. 415) - re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c). (Attachments: #1 Exhibit A, #2 Exhibit Certificate of Service)(Gattuso, Dominick) |
Filing 604 NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Objections and Responses to Plaintiffs' Notice of Deposition to Defendant Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John) |
Filing 603 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Discovery Disputes - re #602 Letter, #486 Letter. (Attachments: #1 Exhibit A, #2 Exhibit B-E)(Gattuso, Dominick) |
Filing 602 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Discovery dispute. (Gattuso, Dominick) |
Pro Hac Vice Attorney Fannyben D. Patel for Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lak) |
Filing 601 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Second Amended Federal Rule of Civil Procedure 26(a)(1) Initial Disclosures filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Pro Hac Vice Attorney Mark H. Remus for Lek Pharmaceuticals d.d., and for Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d), Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam) |
Filing 600 NOTICE to Take Deposition of Srinivas Arutla on December 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 599 NOTICE to Take Deposition of Shital Pathak on December 20, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 598 NOTICE to Take Deposition of Meka Lingam on December 20, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 597 NOTICE to Take Deposition of B.C. Rajesha on December 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 596 NOTICE to Take Deposition of Spiro Spireas on December 16, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 595 NOTICE to Take Deposition of Lokanath Lenka on December 18, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 594 NOTICE to Take Deposition of Basil Theofanopoulos on December 17, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 593 NOTICE to Take Deposition of Venkata Srinivas Pullela on December 17, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 592 NOTICE to Take Deposition of Shrikant Mudgal on December 18, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 591 NOTICE to Take Deposition of Nidhi Bagree on December 16, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 590 NOTICE to Take Deposition of Pritesh Upadhyay on December 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 589 NOTICE to Take Deposition of Makrand Avachat on December 18, 2019 (Amended) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 588 NOTICE to Take Deposition of Girij Singh on December 17, 2019 (Amended) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
SO ORDERED, re #587 MOTION for Pro Hac Vice Appearance of Attorney Fannyben D. Patel filed by Zhejiang Huahai Pharmaceutical Co. Ltd, Prinston Pharmaceutical Inc. Signed by Judge Leonard P. Stark on 12/6/19. (ntl) |
Filing 587 MOTION for Pro Hac Vice Appearance of Attorney Fannyben D. Patel - filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Fineman, Steven) |
Filing 586 NOTICE OF SERVICE of (1) Lupin's Responses and Objections to Plaintiffs' Second Set of Interrogatories (No. 19); and (2) Lupin's Responses and Objections to Plaintiffs' Third Set of Requests for Production (Nos. 186-189) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
Filing 585 NOTICE OF SERVICE of 1) Defendants Cipla Limited and Cipla USA Inc.'s Response to Plaintiffs' Third Set of Requests for the Production of Documents and Things (Nos. 187-190), and 2) Defendants Cipla Limited and Cipla USA Inc.'s Response to Plaintiffs' Second Set of Interrogatories (No. 20) filed by Cipla Limited, Cipla USA Inc..(Vrana, Robert) |
Filing 584 NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s 1) Response to Plaintiffs' Third Set of Requests for Produciton (Nos. 154-155); and 2) Response to Plaintiffs' Second Set of Interrogatories (No. 16) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 583 NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc.'s and Zhejiang Huahai Pharmaceutical Co., Ltd.'s Objections and Responses to Plaintiffs' Third Set of Requests for the Production of Documents and Things (Nos. 113-114) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine) |
Filing 582 NOTICE OF SERVICE of 1) Responses to Second Set of Interrogatories (No. 16) and 2) Responses to Third Set of Requests for Production of Documents and Things (Nos. 157-158) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 581 NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc.'s and Zhejiang Huahai Pharmaceutical Co., Ltd.'s Objections and Responses to Plaintiffs' Second Set of Interrogatories (No. 9) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine) |
Filing 580 NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s (1) Objections and Responses to Plaintiffs' Second Set of Interrogatories (No. 16) and (2) Objections and Responses to Plaintiffs' Third Set of Requests for Production of Documents and Things (Nos. 157-158) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie) |
Filing 579 NOTICE OF SERVICE of (1) Defendant Unichem's Responses and Objections to Plaintiffs' Third Set of Requests to Unichem Laboratories, Limited for the Production of Documents and Things (Nos. 154-155); and (2) Defendant Unichem's Responses and Objections to Plaintiffs' Second Set of Interrogatories to Unichem Laboratories, Limited (No. 15) filed by Unichem Laboratories, Limited.(Haney, Megan) |
Filing 578 NOTICE OF SERVICE of Defendant Sigmapharm Laboratories, LLC's Objections and Responses to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Sigmapharm Laboratories LLC.(Haney, Megan) |
Filing 577 NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' Second Set of Interrogatories (No. 20); and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' Third Set of Requests for the Production of Documents and Things (Nos. 188-191) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 576 NOTICE OF SERVICE of 1) Defendant Alkem Laboratories Ltd.s Response to Plaintiffs Second Set of Interrogatories (No. 16); and 2) Defendant Alkem Laboratories Ltd.s Response to Plaintiffs Third Set of Requests for the Production of Documents and Things (Nos. 157-158) filed by Alkem Laboratories Ltd..(Kraman, Pilar) |
Filing 575 NOTICE OF SERVICE of (1) responses to third set of requests for production and (2) responses to second set of interrogatories filed by Apicore US LLC.(Dorsney, Kenneth) |
Filing 574 NOTICE OF SERVICE of (i) Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Responses and Objections to Plaintiffs' Second Set of Interrogatories (No. 9) and (ii) Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Responses and Objections to Plaintiffs' Third Set of Requests for Production of Documents and Things (Nos. 113-114) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John) |
Filing 573 NOTICE OF SERVICE of (1) Apotex's responses to Plaintiffs' Second Set of Interrogatories (No. 15); and (2) Apotex's responses to Plaintiffs' Third Set of Requests for Production (Nos. 154-155) filed by Apotex Corp., Apotex Inc., Apotex Research Private Limited.(Dorsney, Kenneth) |
Filing 572 ORAL ORDER: Regarding the discovery dispute set forth in D.I. 486, IT IS HEREBY ORDERED that the discovery dispute will be heard during the hearing on December 18, 2019. Discovery letters shall be submitted on December 11, 2019 and December 13, 2019. ORDERED by Judge Leonard P. Stark on 12/4/19. (ntl) |
SO ORDERED, re #571 MOTION for Pro Hac Vice Appearance of Attorney Mark H. Remus filed by Lek Pharmaceuticals d.d., Sandoz Inc. Signed by Judge Leonard P. Stark on 12/4/19. (ntl) |
Filing 571 MOTION for Pro Hac Vice Appearance of Attorney Mark H. Remus - filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick) |
Filing 570 NOTICE OF SERVICE of Plaintiffs' First Supplemental Responses to Defendants' First Set of Common Interrogatories to Plaintiffs (Nos. 1-9) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 569 NOTICE OF SERVICE of (i) Sandoz Inc. and Lek Pharmaceuticals d.d.s Objections and Responses to Plaintiffs Fourth Set of Requests for Production of Documents and Things (Nos. 168-169) [CONFIDENTIAL]; (ii) Sandoz Inc. and Lek Pharmaceuticals d.d.s First Supplemental Responses to Plaintiffs First Set of Interrogatories (Nos. 4-8) [CONFIDENTIAL]; and, (iii) Sandoz Inc. and Lek Pharmaceuticals d.d.s Objections and Responses to Plaintiffs Third Set of Interrogatories (No. 23) [CONFIDENTIAL] filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick) |
Filing 568 NOTICE OF SERVICE of Responses and Objections to Plaintiffs' Notice of Deposition Pursuant to Federal Rule of Civil Procedure 30(b)(6) filed by Unichem Laboratories, Limited.(Haney, Megan) |
Filing 567 NOTICE OF SERVICE of Defendants MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc., and MSN Pharmachem Private Limited Objections and Responses to Notice of Deposition Pursuant to Fed R Civ P 30(b)(6) filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey) |
SO ORDERED, re #561 MOTION for Pro Hac Vice Appearance of Attorney Priscilla G. Dodson and Megan L. Hare filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #564 MOTION for Pro Hac Vice Appearance of Attorney Han Park filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 12/2/19. (ntl) |
Filing 566 NOTICE OF SERVICE of Apotex's Objections to Plaintiffs' 30(b)(6) Deposition Notice filed by Apotex Corp., Apotex Inc..(Dorsney, Kenneth) |
Filing 565 ORAL ORDER: IT IS HEREBY ORDERED that at the hearing on December 18, 2019 each side will have one (1) hour for argument on all issues. ORDERED by Judge Leonard P. Stark on 11/26/19. (ntl) |
Filing 564 MOTION for Pro Hac Vice Appearance of Attorney Han Park - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 563 NOTICE OF SERVICE of [CORRECTED] Plaintiffs' Objections and Responses to Defendant Sandoz Inc.'s First Set of Individual Interrogatories to Plaintiffs (Nos.1-3) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc..(Dellinger, Megan) |
Filing 562 NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendants' Second Set of Common Interrogatories to Plaintiffs (Nos. 10-17) and (2) Plaintiffs' Objections and Responses to Defendants' Third Set of Requests for Production to Plaintiffs (No. 137) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 561 MOTION for Pro Hac Vice Appearance of Attorney Priscilla G. Dodson and Megan L. Hare - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Pro Hac Vice Attorney Jieun Lee for Lek Pharmaceuticals d.d. and Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
Filing 560 NOTICE OF SERVICE of (1)Response to Plaintiff's Notice of Deposition to Jayaraman Kannappan and (2) Response to notice of 30(b)(6) Deposition to Apicore filed by Apicore US LLC.(Dorsney, Kenneth) |
Filing 559 NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.s Objections and Responses to Plaintiffs Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick) |
Filing 558 NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Objections to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Connolly, Arthur) |
Filing 557 NOTICE of Withdrawal of Joshua E. Ney, Ph.D. by Lek Pharmaceuticals d.d., Sandoz Inc. (Gattuso, Dominick) |
Filing 556 NOTICE OF SERVICE of Plaintiffs' First or Second Sets of Requests for Admission to Defendants (addressed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 555 NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s First Set of Requests for Production of Documents to Plaintiffs (Nos. 1-8) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 554 NOTICE OF SERVICE of (1) Unichem Laboratories, Limited's First Set of Individual Interrogatories to Plaintiffs (No. 1); (2) Unichem Laboratories, Limited's First Set of Individual Requests for Production of Documents and Things to Plaintiffs (Nos. 1-4); and (3) Unichem Laboratories, Limited's First Set of Requests for Admission to Plaintiffs (Nos. 1-20) filed by Unichem Laboratories, Limited.(Haney, Megan) |
Filing 553 NOTICE OF SERVICE of Interrogatories directed to individual defendants (See notice for details) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 552 NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.s First Set of Interrogatories to Plaintiffs (Nos. 1-3) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie) |
Filing 551 ORAL ORDER: IT IS HEREBY ORDERED that the Markman Hearing scheduled for November 25, 2019 is CANCELLED and is RESCHEDULED for December 18, 2019 at 12:30 PM. ORDERED by Judge Leonard P. Stark on 11/20/19. (ntl) |
Filing 550 NOTICE OF SERVICE of Defendants Macleods Pharmaceuticals Limited and Macleods Pharma USA Inc.'s First Set of Requests for Admission to Plaintiffs filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 549 NOTICE OF SERVICE of Apotex's First Set of Individual Interrogatories to Plaintiffs (Nos. 1-2) filed by Apotex Corp., Apotex Inc..(Dorsney, Kenneth) |
Pro Hac Vice Attorney Ahmed Abdel-Rahman for Torrent Pharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d), Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam) |
SO ORDERED, re #546 MOTION for Pro Hac Vice Appearance of Attorney Ahmed Abdel-Rahman of Pillsbury Winthrop Shaw Pittman LLP filed by Torrent Pharmaceuticals Limited, Torrent Pharma Inc., #544 MOTION for Pro Hac Vice Appearance of Attorney Jieun Lee filed by Lek Pharmaceuticals d.d., Sandoz Inc. Signed by Judge Leonard P. Stark on 11/19/19. (ntl) |
Filing 548 NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc.'s and Zhejiang Huahai Pharmaceutical Co., Ltd.'s Objections and Responses to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine) |
Filing 547 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' Notice of Deposition Under Federal Rule of Civil Procedure 30(b)(6) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 546 MOTION for Pro Hac Vice Appearance of Attorney Ahmed Abdel-Rahman of Pillsbury Winthrop Shaw Pittman LLP - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Riley, Stephanie) |
Filing 545 NOTICE requesting Clerk to remove Shailendra Maheshwari, Esquire, of the law firm of Pillsbury Winthrop Shaw & Pittman LLP as co-counsel.. (Riley, Stephanie) |
Filing 544 MOTION for Pro Hac Vice Appearance of Attorney Jieun Lee - filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick) |
Filing 543 NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s First Set of Interrogatories to Plaintiffs (Nos. 1-5) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 542 ORDER re #541 Memorandum Order -- #378 Motion for Certification for Interlocutory Appeal filed by Lek Pharmaceuticals d.d., Sandoz Inc. is DENIED. Signed by Judge Leonard P. Stark on 11/15/19. (ntl) |
Filing 541 MEMORANDUM ORDER re #378 Motion for Certification for Interlocutory Appeal filed by Lek Pharmaceuticals d.d., Sandoz Inc. Signed by Judge Leonard P. Stark on 11/15/19. (ntl) |
Filing 540 NOTICE OF SERVICE of Lupin's Responses and Objections to Plaintiffs' Notice of Deposition to Lupin Limited and Lupin Pharmaceuticals Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
Filing 539 NOTICE to Take Deposition of MICHAEL J. MEALY pursuant to Fed. R. Civ. P. 30(b)(1) on December 10, 2019 filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
Filing 538 NOTICE to Take Deposition of MORTEN JORGENSEN pursuant to Fed. R. Civ. P. 30(b)(1) on December 12, 2019 filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
Filing 537 NOTICE to Take Deposition of MICHAEL HAROLD ROCK pursuant to Fed. R. Civ. P. 30(b)(1) on December 11, 2019 filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
Filing 536 NOTICE OF SERVICE of Defendants Par Pharmaceutical Inc.'s and Zhejiang Huahai Pharmaceutical Co., Ltd.'s First Set of Individual Interrogatories to Plaintiffs (Nos. 1-5) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine) |
Filing 535 NOTICE OF SERVICE of Sigmapharm Laboratories, LLC's Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-16) filed by Sigmapharm Laboratories LLC.(Haney, Megan) |
Filing 534 ORDER granting #532 MOTION for Extension of Time to Respond to Plaintiffs' First Set of Interrogatories [UNOPPOSED] - filed by Sigmapharm Laboratories LLC. Signed by Judge Leonard P. Stark on 11/14/19. (etg) |
Filing 533 NOTICE OF SERVICE of (1) Takeda's Objections and Responses to Defendants' Amended Rule 30(b)(6) Notice of Deposition to Takeda and (2) Lundbeck's Objections and Responses to Defendants' Amended Rule 30(b)(6) Notice of Deposition to Lundbeck filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd..(Dellinger, Megan) |
Filing 532 MOTION for Extension of Time to Respond to Plaintiffs' First Set of Interrogatories [UNOPPOSED] - filed by Sigmapharm Laboratories LLC. (Attachments: #1 Text of Proposed Order)(Phillips, John) |
Filing 531 NOTICE to Take Deposition of Y. Ravindra Kumar on December 11, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 530 NOTICE to Take Deposition of Vimal Kaneria on December 3, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 529 NOTICE to Take Deposition of Vijender Gupta on December 13, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 528 NOTICE to Take Deposition of Saumil Shah on December 16, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 527 NOTICE to Take Deposition of Pratap Reddy Padi on December 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 526 NOTICE to Take Deposition of Mehul Patel on December 13, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 525 NOTICE to Take Deposition of Makrand Avachat on December 6, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 524 NOTICE to Take Deposition of Kumar Singh on December 2, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 523 NOTICE to Take Deposition of Jitendra Gajera on December 4, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 522 NOTICE to Take Deposition of Jayaraman Kannappan on December 2, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 521 NOTICE to Take Deposition of Dhananjai Shrivastava on December 11, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 520 NOTICE to Take Deposition of Abhijeet Patil on December 16, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 519 NOTICE to Take Deposition of A.R. Reddy on December 9, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 518 NOTICE to Take Deposition of Shailesh Gohad on December 12, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 517 NOTICE to Take Deposition of Sanjiv Tomer on November 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 516 NOTICE to Take Deposition of Ramesh Gupta on December 12, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 515 NOTICE to Take Deposition of Kondal Reddy Bairy on December 6, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 514 NOTICE to Take Deposition of Girij Singh on December 9, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 513 NOTICE to Take Deposition of Dinesh Kumar on December 17, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 512 NOTICE to Take Deposition of Bijay Padhi on December 20, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 511 NOTICE to Take Deposition of Dusan Teslic on November 18, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 510 NOTICE OF SERVICE of Sigmapharm Laboratories, LLC's Objections and Responses to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 120-156) filed by Sigmapharm Laboratories LLC.(Haney, Megan) |
Filing 509 NOTICE to Take Deposition of B.S. Natarajan on November 18, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 508 NOTICE to Take Deposition of Andreja Kovac on November 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 507 NOTICE OF SERVICE of (1) Apotex's responses to Plaintiffs' First Set of Interrogatories (Nos. 1-14); and (2) Apotex's responses to Plaintiff's Second Set of Requests for Production (Nos. 117-153) filed by Apotex Corp., Apotex Inc..(Dorsney, Kenneth) |
Filing 506 NOTICE OF SERVICE of (1) Defendants' Notice of Deposition of Marianne Dragheim; (2) Defendants' Notice of Deposition of Jesper Kjerulff; (3) Defendants' Notice of Deposition of Benny Bang-Andersen; (4) Defendants' Notice of Deposition of Tine Bryan Stensbol; (5) Defendants' Notice of Deposition of Ask Puschl; (6) Defendants' Notice of Deposition of Heidi Lopez de Diego; and (7) Defendants' Notice of Deposition of Kim Andersen filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 505 NOTICE OF SERVICE of Objections to Notice of Deposition of Defendants Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. pursuant to Fed. R. Civ. P. 30(b)(6) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Mosley, Renee) |
Filing 504 NOTICE of Change of Address for Pro Hac Vice Counsel by Cipla Limited, Cipla USA Inc. (Pascale, Karen) |
Filing 503 NOTICE OF SERVICE of Plaintiffs' Second or Third Sets of Interrogatories and Third or Fourth Sets of Requests for Production of Documents and Things (directed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 502 NOTICE OF SERVICE of (1) Responses to Second Set of Requests for Production and (2) Responses to First Set of Interrogatories filed by Apicore US LLC.(Dorsney, Kenneth) |
Filing 501 NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.'s Objections and Responses to Plaintiffs' Third Set of Requests for Production of Documents and Things (Nos. 131-167) filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick) |
Filing 500 NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Objections and Responses to Plaintiffs' Second Set of Requests for Production of Documents and Things (Nos. 120-156) filed by Torrent Pharmaceuticals Limited.(Riley, Stephanie) |
Filing 499 NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-19); and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 120-187) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 498 NOTICE OF SERVICE of Lupin's Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-18) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
Filing 497 NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.'s Objections and Responses to Plaintiffs' Second Set of Interrogatories (Nos. 9-22) filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick) |
Filing 496 NOTICE of Change of Firm Address of Co-Counsel by Alkem Laboratories Ltd. (Kraman, Pilar) |
Filing 495 NOTICE OF SERVICE of Defendants Macleods Pharmaceuticals, Ltd.s and Macleods Pharma USA, Inc.s Responses to Plaintiffs First Set of Interrogatories to Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Nos.1-15) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 494 NOTICE OF SERVICE of Defendants Cipla Limited and Cipla USA Inc.'s Response to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 119-186) filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen) |
Filing 493 NOTICE OF SERVICE of Responses and Objections to Second Set of Requests for the Production of Documents and Things (Nos. 76-114) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Cragg, Tyler) |
Filing 492 REDACTED VERSION of #458 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 491 NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s Response to Plaintiffs' Second Set of Requests for Production (Nos. 117-153) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 490 NOTICE OF SERVICE of Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc.s Responses to Plaintiffs Second Set of Requests to Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. for the Production of Documents and Things (Nos. 120-156) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly) |
Filing 489 NOTICE OF SERVICE of Defendant Alkem Laboratories Ltd.'s Response to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 120-156) filed by Alkem Laboratories Ltd..(Kraman, Pilar) |
Filing 488 REDACTED VERSION of #446 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 487 ORAL ORDER: IT IS HEREBY ORDERED that the Court will hear argument on the pending motion to dismiss at the same time as the claim construction hearing, which is currently scheduled for November 25 at 9:00 a.m. The Court does not require oral argument on the motion for certification of interlocutory appeal. ORDERED by Judge Leonard P. Stark on 10/25/19. (ntl) |
Filing 486 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Discovery dispute. (Gattuso, Dominick) |
Filing 485 NOTICE OF SERVICE of Lupin's Responses and Objections to Plaintiffs' Second Set of Requests for Production (Nos. 118-185) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
Filing 484 NOTICE OF SERVICE of Defendant Unichem's Responses and Objections to Plaintiffs' Second Set of Requests to Unichem Laboratories, Limited for the Production of Documents and Things (Nos. 117-153) filed by Unichem Laboratories, Limited.(Haney, Megan) |
Filing 483 REDACTED VERSION of #460 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 482 REDACTED VERSION of #452 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 481 REDACTED VERSION of #454 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 480 REDACTED VERSION of #445 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 479 REDACTED VERSION of #456 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 478 NOTICE OF SERVICE of Defendants MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc. and MSN Pharmachem Private Limited's Objection and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-15) filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey) |
Filing 477 REDACTED VERSION of #449 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 476 NOTICE OF SERVICE of Defendant Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Responses and Objections to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 76-114) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John) |
Filing 475 NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-15) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie) |
Filing 474 REDACTED VERSION of #450 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 473 NOTICE OF SERVICE of Defendants Cipla Limited and Cipla USA Inc.'s Response to Plaintiffs' First Set of Interrogatories (Nos. 1 - 19) filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen) |
Filing 472 NOTICE OF SERVICE of Objections and Responses to First Set of Interrogatories (Nos. 1-8) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine) |
Filing 471 NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s Response to Plaintiffs' First Set of Interrogatories (Nos. 1-15) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole) |
Filing 470 NOTICE OF SERVICE of Defendant Unichem's Responses and Objections to Plaintiffs' First Set of Interrogatories to Unichem Laboratories, Limited (Nos. 1-14) filed by Unichem Laboratories, Limited.(Haney, Megan) |
Filing 469 NOTICE OF SERVICE of Defendant Alkem Laboratories Ltd.s Response to Plaintiffs First Set of Interrogatories (Nos. 1-15) filed by Alkem Laboratories Ltd..(Kraman, Pilar) |
Filing 468 NOTICE OF SERVICE of Defendant Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-8) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John) |
Filing 467 REDACTED VERSION of #457 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 466 REDACTED VERSION of #444 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 465 REDACTED VERSION of #448 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 464 REDACTED VERSION of #455 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 463 NOTICE to Take Deposition of Arne Mork on October 29. 2019 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey) |
Filing 462 REDACTED VERSION of #453 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 461 REDACTED VERSION of #451 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 460 [SEALED] NOTICE to Take Deposition of Defendant Sigmapharm Laboratories, LLC (30(b)(6)) on November 15, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 459 CLAIM Construction Chart by Cipla Limited, Cipla USA Inc.. (Attachments: #1 Exhibit 1)(Vrana, Robert) |
Filing 458 [SEALED] NOTICE to Take Deposition of Defendants Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (30(b)(6)) on November 13, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 457 [SEALED] NOTICE to Take Deposition of Defendants Lupin Limited and Lupin Pharmaceuticals, Inc. (30(b)(6)) on November 12, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 456 [SEALED] NOTICE to Take Deposition of Defendants Sandoz Inc., Sandoz AG and LEK Pharmaceuticals, D.D. (30(b)(6)) on November 14, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 455 [SEALED] NOTICE to Take Deposition of Defendant Apicore US LLC (30(b)(6)) on December 2, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 454 [SEALED] NOTICE to Take Deposition of Defendants Hetero (30(b)(6)) on December 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 453 [SEALED] NOTICE to Take Deposition of Defendants Cipla Limited and Cipla USA Inc. (30(b)(6)) on November 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 452 [SEALED] NOTICE to Take Deposition of Defendants Apotex Inc., Apotex Corp., and Apotex Research Private Limited (30(b)(6)) on December 6, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 451 [SEALED] NOTICE to Take Deposition of Defendant Alkem Labs Ltd. (30(b)(6)) on November 8, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 450 [SEALED] NOTICE to Take Deposition of Defendants Alembic Pharmaceuticals Limited, Alembic Global Holding S/A and Alembic Pharmaceuticals, Inc. (30(b)(6)) on November 11, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 449 [SEALED] NOTICE to Take Deposition of Defendants Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd., Inc. (30(b)(6)) on December 20, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 448 [SEALED] NOTICE to Take Deposition of Defendants MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc., and MSN Pharmachem Private Limited (30(b)(6)) on November 21, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 447 CLAIM CONSTRUCTION ANSWERING BRIEF filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 446 [SEALED] NOTICE to Take Deposition of Defendants Torrent Pharmaceuticals Limited & Torrent Pharma Inc. (30(b)(6)) on November 22, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 445 [SEALED] NOTICE to Take Deposition of Defendants Zydus Pharmaceuticals (USA) Inc. & Cadila Healthcare Ltd. (30(b)(6)) on November 18, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 444 [SEALED] NOTICE to Take Deposition of Unichem Laboratories, Limited (30(b)(6)) on December 13, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 443 DECLARATION re #442 Claim Construction Reply Brief Declaration of Judy K. He In Support of Defendants' Responsive Claim Construction Brief by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit 1)(Gattuso, Dominick) |
Filing 442 Joint CLAIM CONSTRUCTION REPLY BRIEF filed by Defendants filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick) |
Filing 441 NOTICE OF SERVICE of Defendants' Second Set of Common Interrogatories to Plaintiffs (Nos. 10-17) and Defendants' Third Set of Requests for Production to Plaintiffs (No. 137) filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick) |
Filing 440 NOTICE OF SERVICE of Sandoz Inc.'s First Set of Individual Interrogatories to Plaintiffs (Nos. 1-3) filed by Sandoz Inc..(Gattuso, Dominick) |
Filing 439 NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's First Amended Federal Rule of Civil Procedure 26(a)(1) Initial Disclosures filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 438 NOTICE OF SERVICE of (1) Defendants' Amended Rule 30(b)(6) Notice of Deposition to Lundbeck; and (2) Defendants' Amended Rule 30(b)(6) Notice of Deposition to Takeda filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Apicore US LLC, Apotex Corp., Apotex Inc., Apotex Research Private Limited, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lek Pharmaceuticals d.d., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Sandoz AG, Sandoz Inc., Sigmapharm Laboratories LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Unichem Laboratories, Limited, Zhejiang Huahai Pharmaceutical Co. Ltd, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 437 REDACTED VERSION of #433 Declaration, of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion for Partial Judgment on the Pleadings Under FEd. R. Civ. P. 12(c) and to Dismiss for Lack of Subject Matter Jurisdiction Under Fed. R. Civ. P. 12(b)(1) by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit Exhibits P-X, #2 Certificate of Service)(Gattuso, Dominick) |
Filing 436 REDACTED VERSION of #432 Reply Brief, In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Partial Judgment on the Pleadings Under Fed. R. Civ. P. 12(c) and to Dismiss for Lack of Subject Matter Jurisdiction Under Fed. R. Civ. P. 12(b)(1) by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Certificate of Service)(Gattuso, Dominick) |
Filing 435 NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s First Set of Individualized Interrogatories to Plaintiffs (Nos. 1-2) and (2) Plaintiffs' Objections and Responses to Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s First Set of Individualized Requests for Admission to Plaintiffs (Nos. 1-10) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 434 REQUEST for Oral Argument by Lek Pharmaceuticals d.d., Sandoz Inc. re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c). (Gattuso, Dominick) |
Filing 433 [SEALED] DECLARATION re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c), #432 Reply Brief, by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit Exhibit P-X [Under Seal], #2 Certificate of Service)(Gattuso, Dominick) |
Filing 432 [SEALED] REPLY BRIEF re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c) filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Certificate of Service)(Gattuso, Dominick) |
Filing 431 NOTICE requesting Clerk to remove Howard S. Suh as co-counsel.. (Dorsney, Kenneth) |
Pro Hac Vice Attorney Nicholas P. Chiara for Apicore US LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
Filing 430 REDACTED VERSION of #426 Answering Brief in Opposition,, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan) |
Filing 429 NOTICE OF SERVICE of Defendant Unichem Laboratories, Limited's Supplemental Disclosures Pursuant to District Court of Delaware Default Standard for Discovery Paragraph 3 filed by Unichem Laboratories, Limited.(Haney, Megan) |
Filing 428 NOTICE requesting Clerk to remove Daisy Manning as co-counsel. Reason for request: No longer working on the case. (Haney, Megan) |
SO ORDERED, re #427 MOTION for Pro Hac Vice Appearance of Attorney Russell W. Faegenburg filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 10/2/19. (ntl) |
Pro Hac Vice Attorney Russell W. Faegenburg for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
Filing 427 MOTION for Pro Hac Vice Appearance of Attorney Russell W. Faegenburg - filed by Alkem Laboratories Ltd.. (Poff, Adam) |
Filing 426 [SEALED] ANSWERING BRIEF in Opposition re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..Reply Brief due date per Local Rules is 10/4/2019. (Attachments: #1 Exhibit A-C)(Dellinger, Megan) |
Filing 425 NOTICE OF SERVICE of (1) Defendants' Rule 30(b)(6) Notice of Deposition to Lundbeck; and (2) Defendants' Rule 30(b)(6) Notice of Deposition to Takeda filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Apicore US LLC, Apotex Corp., Apotex Inc., Apotex Research Private Limited, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lek Pharmaceuticals d.d., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Sandoz Inc., Sigmapharm Laboratories LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Unichem Laboratories, Limited, Zhejiang Huahai Pharmaceutical Co. Ltd, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 424 NOTICE OF SERVICE of Plaintiffs' Second or Third Sets of Requests for Production of Documents and Things to Defendants (addressed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 423 NOTICE OF SERVICE of Plaintiffs' First or Second Sets of Interrogatories to Defendants (addressed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 422 NOTICE requesting Clerk to remove David A. Gerasimow as co-counsel. Reason for request: No long with Husch Blackwell LLP. (Haney, Megan) |
Filing 421 Interim STATUS REPORT by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 420 NOTICE OF SERVICE of Plaintiffs' Responsive Initial Infringement Contentions for U.S. Patent Nos. 9,125,908, and 9,125,909 Against Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co., Ltd. filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 419 REDACTED VERSION of #417 Declaration,, of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion to Dismiss by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A-O, #2 Certificate of Service)(Gattuso, Dominick) |
Filing 418 REDACTED VERSION of #416 Opening Brief in Support, of Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Partial Judgement on the Pleadings Under Fed. R. Civ. P. 12(c) and to Dismiss for Lack of Subject Matter Jurisdiction Under Fed. R. Civ. P. 12(b)(1) by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Certificate of Service)(Gattuso, Dominick) |
Filing 417 [SEALED] DECLARATION re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c) Declaration of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion to Dismiss by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit Exhibits A-O, #2 Certificate of Service)(Gattuso, Dominick) (Attachment 1 replaced on 9/16/2019) (amf). |
Filing 416 [SEALED] OPENING BRIEF in Support re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c) filed by Lek Pharmaceuticals d.d., Sandoz Inc..Answering Brief/Response due date per Local Rules is 9/27/2019. (Attachments: #1 Certificate of Service)(Gattuso, Dominick) |
Filing 415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1), MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c) - filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 [Proposed] Order)(Gattuso, Dominick) |
Filing 414 NOTICE of Appearance by Stephanie S. Riley on behalf of Torrent Pharma Inc., Torrent Pharmaceuticals Limited (Riley, Stephanie) |
CORRECTING ENTRY: D.I. 414 has been deleted at the request of the filer (duplicative of D.I. 413). (etg) |
Filing 413 DECLARATION re #412 Claim Construction Opening Brief [Declaration of Joshua E. Ney] by Sigmapharm Laboratories LLC, Unichem Laboratories, Limited and Zydus Pharmaceuticals. (Attachments: #1 Exhibit 1, #2 Exhibit 2)(Phillips, John) |
Filing 412 CLAIM CONSTRUCTION OPENING BRIEF filed by Sigmapharm Laboratories LLC, Unichem Laboratories, Limited and Zydus Pharmaceuticals. (Phillips, John) |
Filing 411 CLAIM CONSTRUCTION OPENING BRIEF filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-9)(Dellinger, Megan) |
Filing 410 CLAIM Construction Chart by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Attachments: #1 Exhibit 1)(Fineman, Steven) |
Filing 409 NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Second Set of Requests for Production to Plaintiffs (Nos. 95-136) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 408 NOTICE of Withdrawal and Substitution of Co-Counsel by Alkem Laboratories Ltd. (Poff, Adam) |
Filing 407 NOTICE OF SERVICE of Apicore's Revised Paragraph 3 Disclosures filed by Apicore US LLC.(Dorsney, Kenneth) |
Filing 406 NOTICE OF SERVICE of (1) Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s First Set of Individualized Interrogatories to Plaintiffs (Nos. 1-2); and (2) Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s First Set of Individualized Requests for Admission to Plaintiffs (Nos. 1-10) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
Filing 405 REDACTED VERSION of #400 Declaration, Second Declaration of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit T (UNDER SEAL), #2 Exhibit U, #3 Exhibit V, #4 Certificate of Service)(Gattuso, Dominick) |
Filing 404 REDACTED VERSION of #399 Reply Brief, In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Certificate of Service)(Gattuso, Dominick) |
Filing 403 NOTICE OF SERVICE of Defendants' Joint Amended Invalidity Contentions filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Apicore US LLC, Apotex Corp., Apotex Inc., Apotex Research Private Limited, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lek Pharmaceuticals d.d., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Sandoz AG, Sandoz Inc., Sigmapharm Laboratories LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Unichem Laboratories, Limited, Zhejiang Huahai Pharmaceutical Co. Ltd, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 402 NOTICE OF SERVICE of Prinston Pharmaceutical Inc.'s Initial Non-Infringement Contentions for U.S Patent Nos. 9,125,908 and 9,125,909 filed by Prinston Pharmaceutical Inc..(Mowery, Katharine) |
Filing 401 REQUEST for Oral Argument by Lek Pharmaceuticals d.d., Sandoz Inc. re #378 REQUEST for Certification of Direct Appeal to the U.S. Court of Appeals Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal. (Gattuso, Dominick) |
Filing 400 [SEALED] Second DECLARATION re #399 Reply Brief, Second Declaration of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit T, #2 Exhibit U, #3 Exhibit V, #4 Certificate of Service)(Gattuso, Dominick) |
Filing 399 [SEALED] REPLY BRIEF re #378 REQUEST for Certification of Direct Appeal to the U.S. Court of Appeals Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal filed by Lek Pharmaceuticals d.d., Sandoz AG. (Attachments: #1 Certificate of Service)(Gattuso, Dominick) |
Filing 398 REDACTED VERSION of #393 Answering Brief in Opposition,, Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 397 CLAIM Construction Chart by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 2 (Volume 2 - Appendix Exhibits T-CC), #2 Exhibit 2 (Volume 2 - Appendix Exhibits DD-HH))(Dellinger, Megan) |
Filing 396 CLAIM Construction Chart by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1, #2 Exhibit 2 (Volume 1 - Appendix Exhibits A-K), #3 Exhibit 2 (Volume 1 - Appendix Exhibits L-S))(Dellinger, Megan) |
Filing 395 [SEALED] OBJECTIONS by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. to #384 Amended Document, (Plaintiffs' Answer to Alkem's Amended Counterclaims to the Second Amended Complaint). (Dellinger, Megan) |
Filing 394 NOTICE of Change of Address by Kelly E. Farnan (Farnan, Kelly) |
Filing 393 [SEALED] ANSWERING BRIEF in Opposition re #378 REQUEST for Certification of Direct Appeal to the U.S. Court of Appeals Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..Reply Brief due date per Local Rules is 8/20/2019. (Attachments: #1 Exhibit A-F)(Dellinger, Megan) |
Filing 392 NOTICE OF SERVICE of Plaintiffs' Identification of Rebuttal Evidence in Opposition to Defendants' Proposed Constructions of Disputed Terms filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan) |
Filing 391 NOTICE OF SERVICE of Defendants' Revised Preliminary Claim Constructions and Identification of Rebuttal Evidence filed by Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
Filing 390 REDACTED VERSION of #384 Amended Document, // ALKEM'S AMENDED ANSWER, DEFENSES, AND COUNTERCLAIMS TO PLAINTIFFS' SECOND AMENDED COMPLAINT FOR PATENT INFRINGEMENT by Alkem Laboratories Ltd.. (Attachments: #1 Exhibit A and B)(Kraman, Pilar) |
Filing 389 ORAL ORDER: At the request of counsel for Sandoz, IT IS HEREBY ORDERED that the discovery teleconference scheduled for August 15 is CANCELLED. ORDERED by Judge Leonard P. Stark on 8/8/19. (ntl) |
Filing 388 ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for August 15, 2019 at 11:00 a.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than August 9, 2019, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than August 13, 2019, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 8/7/19. (ntl) |
Filing 387 REDACTED VERSION of #379 Declaration, of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A-F, #2 Exhibit G-L, #3 Exhibit M-S, #4 Certificate of Service)(Gattuso, Dominick) |
Filing 386 REDACTED VERSION of #380 Opening Brief in Support, of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick) |
Filing 385 REDACTED VERSION of #371 Answer to Counterclaim [MSN] by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan) |
Filing 384 [SEALED] AMENDED DOCUMENT by Alkem Laboratories Ltd.. Amendment to #344 Answer to Amended Complaint,, Counterclaim, [ALKEM'S AMENDED ANSWER, DEFENSES, AND COUNTERCLAIMS TO PLAINTIFFS' SECOND AMENDED COMPLA |